Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4788 companies, A–Z).
Oppenheimer Holdings subsidiary Viner Finance entered into a lease on November 5, 2026, for about 221,339 rentable square feet at 32 Old Slip in Lower Manhattan, to serve as the firm's principal New York City offices. Fixed annual rent is approximately $13.3 million for the first five years after rent commencement, rising in later periods, and the company expects significant additional capital spending for furniture, equipment and technology tied to the relocation.
Lease covers about 221,339 rentable square feet with an initial term of approximately 15.5 years.
Rent commencement is the later of six months after final delivery of the Premises and July 1, 2028; fixed rent is about $13.3 million a year for the first five years, $14.4 million for the next five, and $15.5 million thereafter.
Viner has an option to terminate at the tenth anniversary of rent commencement for a termination fee of a maximum aggregate of approximately $24 million.
Oppenheimer's press release says phased move-in is targeted to begin in the first quarter of 2028.
Exascale Labs countersigned a $9.04 million firm purchase order for 16 Intel BHS 10U GPU servers with NVIDIA HGX B300 GPUs from Compal Electronics. The filing also describes a framework that would let the company buy up to 128 servers in total, but it places no minimum purchase obligation on the company, and the second order has not been placed. The filing does not describe financial results, and it is not clear how the servers will be funded or used.
Purchase covers 16 servers at $565,000 each, for an aggregate price of $9,040,000 excluding taxes
Down payment of $1,808,000 (20%) due within five business days of Compal's written order confirmation; remaining $7,232,000 (80%) due before shipment
Framework allows purchases of up to 128 servers through March 31, 2027, with no minimum commitment; no order has been placed under the second framework agreement
Company agreed to a storage arrangement and a three-year warranty from Compal; Compal and the company are described as unaffiliated
Aptevo Therapeutics reported on November 9, 2026 that it presented new preclinical data from its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026. The lab results cover APVO451, APVO452 and APVO711, which the company says showed tumor-cell killing and immune activation under conditions that suppress immune responses. The filing contains no financial results, and the data are early-stage, so the update does not change reported financials.
Presentation made on November 7, 2026 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions in preclinical studies.
APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings.
APVO451 and APVO452 are expected to advance into IND-enabling studies in 2027.
Canton Strategic Holdings announced that the first trades of its issuer-sponsored tokenized common stock occurred on November 4, 2026, on TSV LLC's venue on the Canton Network, under the SEC's September 17 Innovation Exemption. The filing contains no financial results, guidance, or financial figures; it describes a new trading and recordkeeping arrangement for the company's shares.
First tokenized CNTN trades executed November 4, 2026 on TSV LLC, with Five North as seller, DRW Cumberland as buyer and Flowdesk as liquidity provider.
Fairmint TA LLC, the company's SEC-registered transfer agent, records the tokenized shares; holders must be verified before holding or trading.
Tokenized shares carry the same rights as CNTN stock traded on Nasdaq, according to the company, and trading is available 24/7 on the venue, subject to stated limits.
First Breach announced a supplier agreement giving it the ability to purchase up to 20 million primers per month, two additional ammunition inspection units, and a separate raw material supply agreement. The company says these steps support plans to scale ammunition production toward up to 20 million rounds per month and move toward 24-hour operations.
Primer agreement allows purchases of up to 20 million primers per month from a strategic supplier
Two additional ammunition inspection units added, supplementing equipment acquired earlier this year at the Hagerstown, Maryland facility
Separate raw material supply agreement announced; no financial terms, dollar values or contract durations were disclosed
Filing is a Regulation FD disclosure furnishing the November 3, 2026 press release; no financial results were reported
On November 5, 2026, the sponsor 21Shares US LLC gave notice to House of Doge Inc. terminating, effective immediately, a Support Services Agreement covering research, data, operational support and marketing services for the trust. The sponsor said it elected to terminate the agreement under its terms. The filing does not state a reason or name a replacement provider, and the terms of the services transition are not described.
Notice given November 5, 2026; termination effective immediately
Agreement is between the sponsor, 21Shares AG and House of Doge Inc.
Services covered include research, data, operational support and marketing for the trust
Filing states the sponsor elected to terminate under the agreement's terms
Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time to review initial clinical data for its NKX019 cell therapy candidate in myositis and systemic sclerosis, presented at the American College of Rheumatology Convergence 2026. The filing contains no financial results, and the company did not disclose the clinical data itself in this document, so shareholders will learn the results at the webcast.
Webcast set for Monday, November 9, 2026, at 8:00 a.m. ET
Initial data covers NKX019 in myositis and systemic sclerosis under the Ntrust program
Data to be presented at ACR Convergence 2026 in Orlando; replay to be archived on Nkarta's investor website
Parabilis Medicines entered into a Third Amendment to its lease for its Cambridge, Massachusetts headquarters, adding 33,525 square feet of space at the neighboring 20 Acorn Park Drive and extending the lease term through December 31, 2037. The filing describes this as a lease change, and it does not state any financial effect on the company's results.
Amendment dated October 30, 2026, with LS 400/500 CDP, LLC, amends the 2019 headquarters lease.
Expansion of 33,525 square feet on the first and sixth floors of 20 Acorn Park Drive begins January 1, 2028, with rent commencing January 1, 2029.
Lease extension term runs from March 1, 2031 to December 31, 2037, with eight months of base rent abatement subject to conditions.
The company gets an option to extend the lease for two additional five-year periods.
Kairos Pharma announced it was named a winner of the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category for its ENV-105 (carotuximab) work in metastatic prostate cancer and non-small cell lung cancer. The filing reports no financial results, guidance, or transaction, so the award itself does not change reported financial figures.
Award: Cancer Immunology Solution of the Year, 2026 Biotech Breakthrough Awards
Lead candidate ENV-105 (carotuximab) is in development for metastatic prostate cancer and non-small cell lung cancer
Press release references earlier positive interim Phase 2 efficacy data for ENV-105 with apalutamide in metastatic castration-resistant prostate cancer
Press release dated November 5, 2026, furnished as Exhibit 99.1
Immunic, Inc. disclosed that it is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET. The company furnished a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms.
PMS R&D Day webinar held via video conference on Thursday, November 5, 2026, 12:30 p.m. to 2:00 p.m. ET
Presentation dated November 5, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Forward-looking statements cite the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 trial in progressive multiple sclerosis
NextTrip announced a broader U.S. rollout of JOURNYGO, its program-linked travel itinerary and booking service, following the initial beta phase. The filing gives no revenue, profit or cost figures, so shareholders have no financial impact to measure yet.
Rollout begins in November 2026 with about 60 content pieces and itineraries, adding JOURNY TV programming and distribution on Samsung TV Plus and Plex.
In the initial test, as many as 30% of viewers clicked through to JOURNYGO.
JOURNYGO content averages nearly 10 minutes of engagement per active user during beta and early use.
Aptevo Therapeutics said successive refinements to the priming-dose regimen for its lead candidate, mipletamig, substantially reduced infusion-related reactions in the ongoing RAINIER study in frontline acute myeloid leukemia. The company said the change supports its preparation for Phase 2 development, which it expects to initiate in 2027, but the filing gives no numerical measure of the reduction and states that the findings do not establish improved efficacy.
Successive priming-dose refinements substantially reduced infusion-related reactions, per the press release; no reduction percentage is disclosed.
Mipletamig data will be presented at the ASH 68th Annual Meeting, December 12-15, 2026, in New Orleans.
Aptevo expects to complete the RAINIER study by year-end 2026 and initiate Phase 2 development in 2027.
Microbot Medical announced that the Canadian Intellectual Property Office granted it a patent for an adaptor that couples a surgical tool such as a guidewire or microcatheter to a motorized robotic surgical device. The company now holds 45 issued patents and 48 patent applications worldwide, including 21 issued patents in North America. The filing contains no financial results, and it does not quantify any effect on sales or revenue.
Canadian Intellectual Property Office granted the patent, announced November 5, 2026
Company holds 45 issued patents and 48 patent applications worldwide as of November 5, 2026
21 of the issued patents are in North America
Company says the patent supports potential future market expansion and regulatory pursuits in additional markets
Genprex reported results from a translational analysis of whole-blood samples from 11 lung cancer patients treated with its lead drug candidate, REQORSA, presented as a poster at the Gerontological Society of America 2026 Annual Scientific Meeting. The company says the findings suggest a shift toward cellular repair and maintenance pathways, but the filing reports no revenue, earnings, guidance, or financing figures, so the news is exploratory and carries no reported financial impact.
Analysis used whole-blood samples from 11 lung cancer patients in two REQORSA clinical trials, taken before treatment and at 5 and 24 hours after infusion.
At 5 hours the response was dominated by innate immune pathways, which the company says is most consistent with a nonspecific reaction to the lipid nanoparticle delivery system.
At 24 hours the profile shifted toward cellular maintenance, and the poster was presented at the GSA meeting taking place November 4-7, 2026, in National Harbor, Maryland.
The filing includes forward-looking warnings and notes that the company's listing compliance on The Nasdaq Capital Market and its ability to continue as a going concern remain risk factors.
Evommune announced a pre-recorded webcast at 8:30 a.m. ET on November 5, 2026, where CEO Luis Peña and management will discuss EVO570, an oral VAV1-directed molecular glue degrader the company in-licensed from Hinova Pharmaceuticals. The filing contains no new financial results or deal terms, but it signals management's focus on the transaction and the planned rheumatoid arthritis development path.
Pre-recorded webcast available at 8:30 a.m. ET on Thursday, November 5, 2026, with an archived replay for 30 days
Exclusive license from Hinova Pharmaceuticals (SSE: 688302) grants worldwide rights to EVO570 outside Greater China
Webcast will not include a live question-and-answer session; questions can go to investor relations
EVO570 is an investigational drug candidate and has not been approved by any regulatory authority
Uranium Energy Corp (UEC) said its subsidiary has entered into definitive long-term sales agreements with two U.S. nuclear utilities covering 1.1 million pounds of uranium concentrates delivered over six years. Each delivery is priced at prevailing spot market prices, so the company stays fully unhedged to future uranium prices. The filing gives no contract value, so the financial effect on shareholders cannot be measured from this document.
Two contracts cover a total of 1,100,000 pounds of uranium concentrates (U3O8), delivered over six years.
One contract delivers 100,000 pounds per year from 2027 through 2032; the other from 2028 through 2032.
All deliveries are priced at prevailing spot market prices; the filing discloses no contract value or floor and ceiling terms.
The company cited a fiscal year 2026 average realized price of $93.13 per pound.
Citius Pharmaceuticals said its majority-owned subsidiary, Citius Oncology, issued a press release on November 4, 2026, presenting health-related quality of life results from pivotal Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma. The data were presented at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026. The filing states the quality of life analyses were exploratory and descriptive, with no formal statistical comparisons, and it contains no financial results or guidance.
Responders (n=25) in the primary analysis set showed mean Skindex-29 Total Score changes from -5.38 to -13.69 points, where lower scores indicate better quality of life.
Responders' FACT-G Total Score change at end of treatment was +3.21, compared with -2.28 for non-responders.
Among 41 patients with a baseline itch score of 20 mm or greater, 13 (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch improvement.
Citius Oncology is partnering with the Cutaneous Lymphoma Foundation on a Quality of Life Workshop scheduled for November 2026.
Emergent BioSolutions received a modification exercising an option period under an existing delivery order, valued at up to $22.3 million, to supply its BioThrax anthrax vaccine to the U.S. Department of War. The filing describes the award as an extension of an existing contract rather than a new financial result, and it does not report revenue, profit, or guidance changes.
Order valued at up to $22.3 million under an existing delivery order and IDIQ contract (W911SR24D0001)
First delivery valued at approximately $7.4 million, beginning this year, with remaining deliveries expected in 2027
Follows an August 2026 contract modification valued at approximately $24 million for CYFENDUS anthrax vaccine to BARDA
On November 4, 2026, Caliber (CaliberCos Inc.) said three more tokenized real estate offerings are live, with up to $85 million of combined offered equity. Investors in these offerings can choose a digital ownership token or a paper certificate, and the filing reports no financial results or guidance. The offerings are limited to accredited investors and are governed by their offering documents.
Three offerings are live: Caliber-Hyatt Studios Steamboat, Caliber-Hyatt Studios Phoenix/TSMC and the Caliber-HS Feeder Fund, with up to $85 million of combined offered equity.
Investors can receive a tokenized digital ownership certificate or keep the existing paper certificate.
With the earlier PURE Pickleball & Padel offering, the four live offerings represent more than $110 million of combined maximum offered equity, against an initial $100 million tokenization target.
Septerna, Inc. (Nasdaq: SEPN) said it selected SEP-204, an oral small molecule TSHR negative allosteric modulator, as a development candidate for Graves' disease and thyroid eye disease, and reported preclinical data ahead of a November 5, 2026 poster presentation at the American Thyroid Association meeting. The company plans to start a Phase 1 trial in healthy volunteers in the first quarter of 2027, but the filing reports no financial results or funding figures.
SEP-204 is designed for once-daily oral dosing, with a projected human half-life of approximately 20-40 hours.
Preclinical data showed selectivity of more than 1000-fold for TSHR over the related FSHR and LHR receptors.
In 28-day GLP toxicology studies in rats and dogs, SEP-204 was generally well tolerated.
Phase 1 trial initiation in healthy volunteers is planned for the first quarter of 2027.
Genprex announced that preclinical and supportive clinical research identifies TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, REQORSA. The poster is scheduled for presentation at the 2026 EORTC-NCI-AACR Symposium in Barcelona, and the company says further research and prospective clinical evaluation are required before TROP2's predictive value is established.
Poster titled TROP2 Predicts Response to TUSC2 Gene Therapy is scheduled for Nov. 18, 2026 in Barcelona, Spain (Abstract 108, Board PB-108).
Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery.
The filing states the findings are preclinical with supportive clinical evidence and that additional research is needed to establish predictive utility.
The filing contains no financial results, guidance, or financing terms.
D-Wave announced performance enhancements to its Stride hybrid solver, which it says found better solutions in 15 seconds than the previous version found in 120 seconds in key benchmark testing. The company also launched a three-course Applied Quantum Optimization learning path for developers. The filing contains no financial results, guidance, or deal terms, so the news is a product and training update with no stated direct financial effect on shareholders.
Enhanced Stride solver, now available in the Leap quantum cloud service, found better solutions in 15 seconds than the previous version found in 120 seconds in key benchmarks.
Traveling salesperson problems with up to 10,000 locations: solutions averaged within 0.02% of the best possible result in 15 seconds, more than 200x closer than the previous solver at the same runtime.
New three-course Applied Quantum Optimization learning path is available today through the Leap quantum cloud service.
Announced November 4, 2026 via Form 8-K Item 7.01 and Exhibit 99.1.
NeOnc Technologies Holdings announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on November 13, 2026, at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. The filing is an announcement of scheduled presentations and contains no financial results, guidance, or new financing terms.
Two poster presentations scheduled for Friday, November 13, 2026, 7:30 to 9:30 p.m. EST, at the Pennsylvania Convention Center in Philadelphia
NEO100 poster: updated Phase 1/2a results in recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, presented by Thomas C. Chen, MD, PhD
NEO212 poster: Phase 1 safety, pharmacokinetics and early activity signals in TMZ-Resistant recurrent GBM, presented by Josh Neman, PhD
Both NEO100 and NEO212 remain investigational and have not been approved by any regulatory authority
Profound Medical's U.S. subsidiary appointed Cook Medical as a non-exclusive distributor of the TULSA-PRO system in the United States, for use with Cook's intraoperative MRI equipment. The filing does not disclose financial terms, and the initial five-year term does not start until FDA clearance for use with Cook's equipment is provided, so the deal's effect on shareholders depends on that clearance and on sales volumes.
Agreement dated October 28, 2026, effective October 23, 2026; Cook is a non-exclusive U.S. distributor of TULSA-PRO for use with Cook's iMRI equipment.
The five-year initial term begins on the date Profound provides Cook with written evidence of FDA clearance; Cook may terminate without liability if that has not occurred by April 30, 2027.
Cook will buy TULSA-PRO systems at a predetermined transfer price, while Profound keeps single-use disposables and service contract revenue from customers who buy through Cook.
The filing does not disclose purchase volumes, transfer prices or other dollar figures.
Cenntro said it delivered 20 LS450 electric trucks in the United States under the New York Truck Voucher Incentive Program, generating more than $2.44 million in total revenue. The LS450 also qualified for California and New Jersey incentive programs, which the company says could broaden customer access to incentives.
20 LS450 electric trucks delivered under the New York Truck Voucher Incentive Program (NYTVIP)
More than $2.44 million in total revenue from these deliveries
Company plans LS450 deliveries under the New York City Clean Trucks Program (NYCCTP)
LS450 listed under California Clean Fuel Reward and New Jersey Zero-Emission Incentive Program
SurgePays said it signed a prepaid wireless purchase agreement on September 30, 2026 with Zulie Venture Inc. (dba Etime system), which committed to buy at least $48 million in prepaid wireless volume from October 1, 2026 through September 30, 2027. The company warned that the net revenue and gross profit it recognizes from this volume may be significantly lower than the stated volume, and that Etime system's commitment is not assured.
Etime system committed to a minimum of $4 million per month, with shortfalls to be made up by the end of the following month.
The agreement renews automatically for successive twelve-month terms unless either party gives notice at least thirty days before the term ends.
Transactions began in October 2026 and are processed through SurgePays POS.
The filing states that volume is not revenue and that net revenue and gross profit may be significantly lower.
UFP Industries said its Deckorators brand has expanded its distribution partnership with Wausau Supply Company, extending Deckorators decking and railing products across Wausau's full network of dealers in 42 states. The filing furnishes a press release and contains no financial results, guidance or dollar figures, so the effect on UFP's financial performance is not quantified.
Expansion announced November 2, 2026, building on a partnership established in February 2025 in seven states.
Wausau Supply operates more than 20 distribution centers serving dealers in 42 states and Canada.
Deckorators will be distributed through a three-partner network with ProWood and Forest Products Supply, which the company says reaches all 50 states.
XMax entered into a five-year GPU computing services agreement with DSH Hyper Pte. Ltd., which will supply dedicated capacity sourced from kt cloud in Korea, with service starting October 29, 2026. Total scheduled charges are about $122.5 million, but the long-term commitment depends on board approval and delivery of security by November 17, 2026, and the company's press release projects more than $100 million in cumulative revenue from related businesses over five years.
Initial configuration of 60 NVIDIA B300 nodes (480 GPUs) and 300 TB of storage, expanding to 64 nodes (512 GPUs) and 560 TB; expansion components become billable only after acceptance testing.
Total scheduled charges of about KRW 162.3 billion (about US$122.5 million) over a 60-month term ending October 28, 2031, excluding taxes.
First payment of about US$2.1 million is due November 6, 2026 as a non-refundable setup fee; if closing conditions are not met, it is the company's sole liability.
Company must provide a standby letter of credit of about US$8.2 million and a corporate guarantee to KT, subject to board approval and delivery by November 17, 2026.
Eton Pharmaceuticals announced ET-900, a new development program evaluating its mecasermin injection, the active ingredient in INCRELEX, for infantile and epileptic spasms, and said it licensed related patent rights from Baylor College of Medicine. A research Investigational New Drug application has been submitted to the FDA for an investigator-sponsored Phase 2 study, with initial enrollment and dosing targeted for the first quarter of 2027. The filing contains no financial figures, so its near-term financial effect is not quantified, and Eton retains commercial rights to ET-900 according to the press release.
Research IND submitted to the FDA for an investigator-sponsored Phase 2 study of mecasermin in children with refractory epileptic spasms
Study expected to enroll up to 20 patients ages 2–18 across three sites: University of Chicago, Baylor College of Medicine, and UCLA
Initial enrollment and patient dosing targeted for the first quarter of 2027
Preclinical animal data cited in the press release showed approximately 50% reduction in daily spasm counts
Precision Optics Corporation entered a one-year lease with Equity Assets, Inc. for its existing 12,292-square-foot Gardner, Massachusetts location, with a term starting July 1, 2026. Monthly base rent rises from $13,316.33 to $13,715.82 on January 1, 2027, and the lease includes two one-year extension options.
Lease signed October 28, 2026; term commences July 1, 2026 for one year
Monthly rent is $13,316.33 through December 31, 2026, then $13,715.82 in 2027, with 3.0% annual increases after that
Company pays personal property taxes; landlord pays real estate taxes and assessments
Two one-year extension options require at least six months' prior written notice
A Pro-Dex subsidiary, Advanced Precision Machining, renewed three existing Costa Mesa, California leases through September 30, 2030, with base rent increases starting February 1, 2027. It also signed a new lease for an industrial unit of about 5,800 square feet starting November 1, 2026. The filing describes routine facility agreements and does not report financial results, so it gives shareholders no direct earnings information.
Lease Renewals signed October 26, 2026, covering about 2,500 square feet at 1645, 1647 and 1649 Monrovia Avenue, extending the leases to September 30, 2030
Base rent rises 4.0% to 6.6% starting February 1, 2027; for spaces 1647 and 1649, rent is $5,651 per month, and for space 1645, $5,513 per month, through October 31, 2028
New Lease signed October 29, 2026 with Salter Family Trust for about 5,800 square feet at 921-923 Newhall Street, with base rent of $11,600 per month from November 1, 2026
Hashdex Nasdaq CME Crypto Index ETF (NCIQ) disclosed that on October 27, 2026, Jane Street Capital, LLC, one of its Authorized Participants, entered into an agreement with the Trust and its sponsor, Hashdex Asset Management Ltd. The agreement sets out the procedures for creating and redeeming Baskets of Common Shares. The filing is administrative and includes no financial results, fees, or dollar amounts.
Agreement dated October 27, 2026, between Jane Street Capital, LLC, the Trust and Hashdex Asset Management Ltd.
Agreement governs how Jane Street creates and redeems Baskets of Common Shares.
Full agreement filed as Exhibit 10.1 to the Form 8-K, signed October 30, 2026.
Green Plains entered into a Tax Credit Purchase Agreement on October 29, 2026, to transfer Section 45Z clean fuel production tax credits from its 2026 ethanol production to two unaffiliated buyers. The deal covers a minimum of $250 million and up to $325 million in credits, and the company expects $140 million of cash in the fourth quarter for credits generated through June 30, 2026.
Minimum of $250 million and maximum of $325 million in 2026 Section 45Z credits, subject to generation and conditions
Company expects $140 million cash in Q4 2026 for credits generated through June 30, 2026
Credits from Q3 and Q4 2026 expected to be monetized in the first half of 2027
If a tax law change limits transferred credits, Green Plains must return the related purchase price with interest
Moleculin Biotech announced that dosing is complete in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia. The company says it remains on track to report comprehensive Part A data in the first quarter of 2027, with the full 90-patient population used to select the Annamycin dose for Part B.
Dosing completed in Part A of the MIRACLE trial, which the company describes as a randomized, double-blind study with a 90-patient Part A population.
Comprehensive Part A data readout remains expected in the first quarter of 2027.
Final Part A population is expected to be about 50/50 between 7+3 chemotherapy and venetoclax-based regimen patients, versus about 70/30 among the first 45 subjects.
The filing states the company will require significant additional financing, for which it has no commitments.
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX on October 26, 2026, under which ZEO would receive an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, with Pluri receiving equity in ZEO at closing. On October 27, 2026, Pluri agreed to sell 909,092 common shares and warrants to two investors for $1.0 million in total, with closing expected on or before October 30, 2026. The stock sale adds shares outstanding, and the ZEO transaction depends on closing conditions, including agreement on an operating plan.
October 26, 2026: ZEO partnership grants ZEO an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, excluding certain aesthetics, skin care, cosmetic, or veterinary uses, which ZEO may only commerci
At closing, Pluri is to receive 41% of ZEO's issued and outstanding shares plus 50 Series D Preferred shares carrying 51% of ZEO's votes
October 27, 2026: two Securities Purchase Agreements for 909,092 common shares at $1.10 per share, with warrants for an equal number of shares at $1.30 per share; closing expected on or before October 30, 2026
Dermata Therapeutics said it enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment, in people with acne. The company expects to launch this second commercial product in the first half of 2027, and the filing ties the plan to a broader shift toward commercializing skincare products. The filing gives no financial figures, so the update is a development milestone rather than a change to reported results.
First participant enrolled in a clinical trial of Tome Clearing Treatment in people with acne, announced October 29
Tome Clearing Treatment is described as the company's once-weekly acne treatment and its second commercial product
Company expects to launch the product in the first half of 2027
Iovance updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial in previously treated non-squamous metastatic non-small-cell lung cancer, reporting a 24.6% objective response rate in 69 patients, consistent with the 25.6% previously reported. The company also introduced a retrospectively identified biomarker subgroup with a 59.1% response rate, a precision strategy that could change how the lung cancer program is developed and how the company plans its next trial.
Broader population: 24.6% objective response rate (17 of 69 patients), consistent with the 25.6% rate in 39 patients previously reported.
Retrospective biomarker subgroup (KRAS wild-type, HER2 wild-type, current or former smoker): 59.1% response rate (13 of 22 patients), including both complete responses.
POSITILITY study to begin enrollment in November 2026; supplemental Biologics License Application for non-squamous mNSCLC planned for 2027, subject to FDA discussions.
Eva Live Inc. announced on October 27, 2026 the launch of EvaSportsPredict, an AI-powered sports prediction platform covering baseball, football, hockey and basketball. The filing gives no financial figures for the product, so its effect on revenue or earnings cannot be measured from this document, though the company says it uses a subscription model and plans more Eva-powered products over the next several weeks.
Standard membership costs $19.99 per month after a 14-day free trial.
Supports professional and college baseball, football, hockey and basketball, with a separate model for each sport.
Company plans to introduce additional Eva-powered products over the next several weeks.
The 8-K was signed October 29, 2026 by David Boulette, President and CEO, and attaches the press release as Exhibit 99.1.
On October 28, 2026, Workhorse Group entered a Manufacturing Spec Unit Purchase Agreement under which UK-based RHAELM will pay $10 million over three installments to build a full-scale TerraPod manufacturing spec unit at the company's Union City, Indiana facility. A non-binding letter of intent targets a definitive supply agreement by December 31, 2026, and contemplates a contingent initial order for 150 TerraPod systems, but the filing states there is no assurance either will happen.
RHAELM will pay $10 million over three installments for a TerraPod manufacturing spec unit at Union City, Indiana.
Non-binding letter of intent targets signing a definitive supply agreement by December 31, 2026.
Contemplated contingent initial order for 150 TerraPod systems depends on the supply agreement, RHAELM's acceptance of the platform, definitive documentation and internal approvals.
Press release says Workhorse believes TerraPod production can begin in late 2027 or early 2028.
Mineralys Therapeutics and Tanabe Pharma terminated the License Agreement for lorundrostat on October 27, 2026, and Tanabe assigned the related patents and know-how to Mineralys. Mineralys remains obligated to pay Tanabe the milestone payments under a separate Payment Obligation Agreement, and Tanabe keeps a first-negotiation right for Japan. The filing says the company incurred no material early termination penalties, and the $100.0 million change-of-control payment is no longer tied to the license terms that existed before.
License Agreement terminated and Transferred Intellectual Property assigned to Mineralys on October 27, 2026
Mineralys still owes Tanabe commercial milestone payments of up to $255.0 million plus up to $10.0 million for a potential second indication
Tanabe's right of first negotiation survives for Japan while milestones remain unpaid
No material early termination penalties incurred; full agreements to be filed with the 2026 Form 10-K
Celularity Inc. announced on October 29, 2026, an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to make U.S.-based peptide active pharmaceutical ingredients under Vesalius's Peptual brand at Celularity's New Jersey facility. The filing does not disclose any financial terms, revenue expectations or contract value, so its effect on Celularity's financial results cannot be assessed from the filing.
Announced October 29, 2026; press release filed as Exhibit 99.1 to Form 8-K
Celularity performs downstream purification, processing, analytical testing and manufacturing at its Florham Park, New Jersey facility
Supply to U.S. compounding pharmacies is conditional on future FDA action following Pharmacy Compounding Advisory Committee recommendations
The collaboration will not involve GLP-1 receptor agonists or other weight-loss peptides
374Water Inc. furnished an updated October 2026 investor presentation and a related press release, both tied to the EPA's PFAS TECH Strategy launched October 26, 2026, which names supercritical water oxidation among technologies to advance. The filing contains no new financial results, guidance, or contract financial terms beyond previously referenced project figures, so the direct financial impact on shareholders is not quantified.
EPA Administrator Lee Zeldin launched the PFAS TECH Strategy on October 26, 2026, naming supercritical water oxidation among technologies to advance.
The presentation cites a U.S. Army Corps of Engineers report documenting 99.9993% total PFAS destruction in AFFF.
The filing lists a City of Olathe, KS order of about $4.8 million and a Mobile WDS contract with St. Cloud, MN of $600,000 completed in September 2026.
Orange County Sanitation District, CA AirSCWO deployment is planned for November 2026.
Canton Strategic Holdings announced an agreement with TSV LLC to make its common stock available for trading on TSV, a venue for tokenized NMS stocks on the Canton Network. Trading is expected to begin as early as Monday, November 2, and the shares would be tokenized by Fairmint as issuer-sponsored stock. The filing contains no financial results, and the company states the tokenized shares would carry the same rights as its Nasdaq-listed stock.
Trading on TSV is expected to begin as early as Monday, November 2, 2026.
Fairmint, an SEC-registered onchain transfer agent, will tokenize the shares as issuer-sponsored stock.
The company says tokenized holders would have the same rights and privileges as holders of its Nasdaq-listed stock.
The announcement follows the SEC's September 17 Innovation Exemption; the filing reports no financial figures.
Evolution Metals & Technologies (EMAT) announced it has secured about 754 metric tons of neodymium metal sourced outside China, which it says covers about 50% of the feedstock needed for its full-year 2027 revenue guidance of $400 million to $460 million. The filing is a furnished press release with no new financial results, so it gives no evidence yet that the feedstock supply is converting into revenue.
About 754 metric tons of neodymium metal secured, including about 42 metric tons already delivered to Pohang and a 600-metric-ton contract with Senri Trading.
About 520 kilograms of dysprosium metal held in Pohang, with 1.5 metric tons per month committed starting February 2027.
Company targets profitability in 2027 and plans a ribbon-cutting ceremony at Pohang on December 17, 2026.
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical on October 23, 2026, for the late-stage calpain inhibitor KIO-401, covering territories outside Asia. The deal calls for a $3.5 million upfront payment, a low-teen-million-dollar payment on technology transfer, and up to $168.5 million in milestones, and the company says it is evaluating financing to fund development. For shareholders, the filing adds near-term cash obligations and funding uncertainty, and it reports no revenue or earnings figures.
Upfront payment of $3.5 million to Senju, with a further low-teen-million-dollar payment upon technology transfer, a portion of which may be credited against future milestones.
Up to $168.5 million in additional regulatory and commercial milestone payments, plus single-digit royalties on net sales in the licensed territory.
Kiora discontinued research and development of KIO-104 and is evaluating financing alternatives to fund KIO-401 development.
Target initiation of the multinational Phase 3 CRAO trial is 2027, subject to funding and regulatory alignment.
Evolution Metals & Technologies (EMAT) said it submitted a capability statement to the U.S. Army's Sources Sought notice for rare earth magnets used in small drone motors. The notice is a market research request that does not commit the Army to any purchase, so the filing reports a submission rather than a contract award.
Submitted a capability statement on October 28, 2026, in response to the Army Contracting Command Sources Sought notice
The company says it commercially produces N42SH, one of the two grades the Army specified, at its Pohang, Korea facility
Plans to expand annual magnet capacity in Pohang from approximately 1,000 metric tons to approximately 10,000 metric tons, pending installation of ULVAC equipment
The Army notice states it is for planning purposes only and does not commit the Government to contract for any supply
Markel's insurance subsidiaries entered an Adverse Development Cover Agreement with Cavello Bay Reinsurance, a wholly owned subsidiary of Enstar Group Limited, covering $4.8 billion of net reserves on a run-off global reinsurance portfolio and certain exited lines. Markel will pay a $2.4 billion reinsurance premium, settled through a transfer of assets at closing, and the deal is expected to close by the end of the fourth quarter of 2026 subject to regulatory approval. Markel's press release says the net impact on fourth quarter underwriting results is expected to be immaterial.
Subject reserves of $4.8 billion; Markel retains the first $2.6 billion of covered losses, and the reinsurer covers the next $2.3 billion.
Adverse development coverage of $1.2 billion above the $4.8 billion of reserves.
Reinsurance premium of $2.4 billion, with $500 million of transferred assets sent to the reinsurer outright and the balance placed in a trust account.
Closing expected by the end of the fourth quarter of 2026, subject to regulatory approval; the agreement covers losses paid on or after April 1, 2026.
MetaVia Inc. announced that an abstract on Phase 1 clinical trial data for DA-1726, a dual GLP-1 and glucagon receptor agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver, Colorado. The filing is an update on a clinical program and contains no financial results, guidance, or transaction terms.
Presentation is scheduled for November 4, 2026, at 1:35 pm MT at the Hilton Denver City Center.
Chief Medical Officer Sarah Browne, M.D., will present the data.
The presentation title cites reduction in MRI-PDFF and weight loss with relative preservation of lean mass in a randomized placebo-controlled trial.
A poster will be posted on the MetaVia website after the presentation.
EM&T reported that all 57 containers of ULVAC sintered magnet-production equipment have arrived at its expanded Pohang, South Korea facility, with commissioning scheduled to begin in November 2026. The company also signed an investment framework with Pohang City that it expects to bring approximately US$28 million in local government grant funding. The filing is an operational update with no financial results, so it gives shareholders no new revenue, profit or guidance figures.
All 57 containers of ULVAC equipment have arrived at the Pohang facility; commissioning is scheduled to begin in November 2026.
The company expects planned capacity to rise from approximately 1,000 to approximately 10,000 metric tons annually, once installation and commissioning are completed.
An investment framework with Pohang City was signed on October 27, 2026; approximately US$28 million in local government grant funding is expected, subject to conditions.
A ribbon-cutting ceremony and operational showcase is scheduled for December 17, 2026.
D-Wave and South Korean AI company LG CNS signed a non-binding memorandum of understanding to advance adoption of D-Wave's annealing quantum computing for enterprise optimization in South Korea and internationally. The separate announcement that customer Shionogi won a NEDO Challenge prize is a collaboration milestone, and the filing gives no financial terms or revenue figures for either item.
MOU with LG CNS announced October 28, 2026 at D-Wave's Qubits Asia conference in Seoul; it is non-binding.
Companies plan joint applications for manufacturing, telecommunications, finance and retail customers and joint go-to-market efforts.
Customer Shionogi won first place in the NEDO Challenge Quality of Life category, with a ¥40 million prize.
In a Scientific Reports study, 97% of molecules generated by the quantum-assisted model were chemically valid, versus 73% for an equivalent classical model.
Genprex said research from its sponsored collaboration with Meharry Medical College will be featured at the Gerontological Society of America 2026 Annual Scientific Meeting, November 4-7, 2026. The work examines the TUSC2 gene, used in its lead oncology candidate REQORSA, in mitochondrial biology and aging-related processes. The company said further research is needed to determine whether the findings could support future therapeutic development.
Poster titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for Wednesday, Nov. 4, 2026, 6:00-7:15 p.m. ET
Presenter is Mark S. Berger, MD, Chief Medical Officer of Genprex
Collaboration with Meharry Medical College was established in 2024
The filing does not state any financial terms or effects on the company's results
Atrium Therapeutics announced that the first patient has been dosed in the Phase 1/2 Corventis trial of ATR 1072, its lead investigational therapy for PRKAG2 syndrome, a rare genetic heart disease with no approved therapies. The company expects initial proof-of-concept data in the second half of 2027, so the milestone does not yet bear on the company's clinical or financial results.
First patient dosed in the Corventis trial, announced October 27, 2026
Global trial plans to enroll approximately 37 participants
Initial proof-of-concept data expected in the second half of 2027
Primary endpoint is incidence of treatment-emergent adverse events
CDT Equity entered an evaluation agreement dated October 22, 2026, under which Manoira Corporation will assess CDT's clinical-stage compounds AZD1656 and AZD5904 for its animal healthcare products. CDT issued 1,347,616 common shares at $0.1447 per share to settle a $195,000 payment due to Manoira, and the filing also reports other share issuances in the same period. Because the deal is an evaluation with no stated licensing terms yet, its value to shareholders is not yet clear, while the share issuances add to the number of shares outstanding.
Evaluation agreement with Manoira dated October 22, 2026; Manoira is preparing a first range of animal health products for launch in the first quarter of 2027.
1,347,616 shares issued at $0.1447 per share to settle a $195,000 payment to Manoira.
Other unregistered issuances: 397,374 shares to a service provider, 437,779 shares to Sarborg Limited, and 499,616 shares to former CEO Dr. Andrew Regan in lieu of $65,000 severance.
Dr. Regan, a more-than-5% holder and sole director of Manoira, will receive no consideration from the Manoira deal; the filing lists one date as October 23, 3026, which appears to be a typo.
60 Degrees Pharmaceuticals announced clinical improvement and negative conventional PCR results in all five patients who completed treatment in its expanded access babesiosis study, with four of five also NAT-negative on a highly sensitive post-treatment test. The company says the study remains open pending potential discussions with the FDA, and the filing reports no financial results, so the update is clinical and regulatory rather than a measure of current business performance.
All five completed patients were much or very much improved and tested negative on conventional PCR
Four of five completed patients (80%) were nonreactive on post-treatment blood-donor NAT testing
Two additional patients remain on treatment, bringing total enrollment to seven
Tafenoquine is not FDA-approved for babesiosis; the hospital-setting randomized study is expected to unblind in January 2027
Perpetua Resources amended warrants covering 1,607,802 common shares, extending each expiry by up to six months. Its subsidiary also entered a cost-share Tungsten OTIA with the U.S. Army to evaluate tungsten concentrate production at the Stibnite Mining District, with a total estimated cost of up to about $85 million and a cost-share of up to $45 million. The filing gives shareholders a clearer view of potential dilution timing and a new federal-funded exploration program, though the filing notes later phases depend on future approvals and results.
Warrants for 1,607,802 common shares at $31.46 and $38.93 had original expiries of October 28, December 1 and December 23, 2026; each is extended by up to six months.
Tungsten OTIA total estimated cost is up to about $85 million, with cost-share of up to $45 million over a period ending October 19, 2029.
Subsidiary Perpetua Resources Idaho will match the U.S. Army's $40 million contribution; the initial 18-month phase is expected to cost about $18 million, shared equally.
LQR House said its subsidiary YHC AI Limited signed a supplemental agreement giving Fusion Five access to several OpenAI GPT models and raising the ceiling on AI compute purchases under an agreement announced October 19. The filing contains no revenue, earnings, or financial impact figures, so its effect on shareholders is not quantified.
Agreement builds on the up to $3 million AI computing resources deal announced October 19, 2026.
Access covers GPT-6 Astra, GPT-6 Sol, GPT-5.6 Luna, and GPT-5.6 Sol models.
Volume discount of 40% off headline price for purchases between $3 million and $5 million; original 30% discount applies below $3 million.
Filing furnished under Item 7.01 and not deemed filed under Section 18 of the Exchange Act.
Forum Markets said its joint venture Forum Edge AI LLC signed a definitive agreement with Fireworks for a 36-month reservation of Nvidia B300 GPU capacity at a Dallas data center, with a combined total contract value of approximately $94.4 million. The company described it as the first finalized contract for Forum Edge and said the GPUs are expected to be deployed in late December or early January. The filing gives no revenue, profit or cash flow figures, so the contract's effect on the company's financial results cannot be measured from this filing.
Contract value of approximately $94.4 million over a 36-month term
Covers reservation of 96 enterprise AI servers at Edge Node's Dallas data center, per the 8-K body; press release cites Nvidia B300 GPU capacity
Fireworks provided a substantial prepayment deposit, to be credited against fees due
GPU deployment expected in late December or early January; first contracted customer commitment for Forum Edge
SS Innovations said its SSi Mantra robotic system and SSi MantrAsana tele-surgeon console were used in telesurgeries at two October 2026 medical conferences, in Barcelona and New Delhi. The filing is a promotional update and contains no financial results, guidance or financial statements, so it gives shareholders no new financial measures to assess.
Dr. Sudhir Srivastava performed a robotic cardiac telesurgery at the EACTS Annual Meeting in Barcelona, with the patient about 7,500 miles away in Bengaluru, India.
Four surgeons completed four robotic-assisted telesurgeries at the inaugural SRS India Conference in New Delhi.
As of October 23, 2026, a total of 205 telesurgeries had been performed with the SSi Mantra surgical robotic system.
Treasure Global's subsidiary Tadaa Technologies signed a Software Development Agreement on October 21, 2026, with Techcom Vintage Sdn Bhd to build a centralized fertilizer subsidy traceability and AI agriculture platform. Tadaa will pay fixed fees of RM8,000,000 in six milestone payments, and the Developer must deliver the platform in phases over about ten months from the effective date.
Fixed software development fees of RM8,000,000, with a mobilization payment of RM4,000,000 due within two business days after signing
Five delivery phases, with Phase 1 due within one month of October 21, 2026 and final integration due within ten months
Developer pays liquidated damages of 2% of a delayed phase's value per week, capped at 10%; Tadaa owns the resulting intellectual property
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial of oral ifetroban in patients with systemic sclerosis, a rare disease. The company said the results support the drug's safety and tolerability in this population. The filing does not include efficacy data, financial figures, or guidance.
Trial: Phase 2a ASSIST-SSc evaluating oral ifetroban for systemic sclerosis
Announced October 23, 2026, with the press release furnished as Exhibit 99.1
Company states results support safety and tolerability of ifetroban in this rare disease population
Allegiant Air, a subsidiary of Allegiant Travel Company, exercised the first six options under its 2021 Boeing purchase agreement, with the six 737-8 aircraft scheduled for delivery in 2028, at a list price of more than $720 million before discounts and escalations. The company also entered into new employment agreements with four executive officers, including CEO Gregory Anderson, that run through the end of 2029.
Options for six 737-8 aircraft exercised; after this, the purchase agreement has 56 firm aircraft (22 delivered through October 23, 2026) and 74 remaining options.
List price of the six aircraft totals more than $720 million, subject to discounts and price escalations through delivery.
Agreements dated as of October 22, 2026 for Gregory Anderson (CEO, $750,000 base salary, 180% target cash bonus), Robert Neal (president and CFO, $525,000), and Drew Wells and Tyler Hollingsworth ($475,000 each).
All four employment agreements expire at the end of 2029; the Anderson agreement supersedes his 2024 agreement.
High Roller Technologies announced the commercial launch of ROLR, its real-money prediction markets platform, for eligible U.S. customers following a closed beta that began September 15, 2026. The company expects the prediction markets business to begin contributing revenue in the fourth quarter of 2026, a timeline the filing presents as expected rather than confirmed.
Commercial launch announced October 21, 2026, after an invitation-only beta that began September 15, 2026
Prediction markets business expected to contribute revenue beginning in Q4 2026; no revenue figures disclosed
Platform offers event-based contracts from Crypto.com | Derivatives North America; customer accounts are carried by Crypto.com FCM
Marketing partners include Lines.com, Forever Network, Leverage Game Media and SpikeUp Media
Lee Enterprises and its majority-owned subsidiary BLOX Digital each signed a three-year Master Service Agreement with Quintype Solutions LLC on October 16, 2026, for software development services. Quintype is a related party because Quint Digital, which owns about 14.38% of Lee's common stock, holds more than a 10% membership interest in it. The company expects the engagements to generate aggregate annual net savings of more than $1 million once fully implemented, with no minimum spending commitment.
Agreements dated October 16, 2026, were signed by Lee and BLOX Digital, each with Quintype Solutions LLC, for software development services.
Each agreement has a three-year initial term, renews automatically for one-year terms, and bills on a time-and-materials basis with no minimum spend.
Lee expects aggregate annual net savings of more than $1 million once fully implemented; liability is generally capped at fees paid over the prior 24 months.
Sponsor 21Shares US LLC gave notice on October 16, 2026 to terminate its marketing and sub-advisory agreement with ARK Investment Management, effective December 22, 2026. The Trust plans to rename itself 21Shares Bitcoin ETF and change its Cboe BZX ticker from ARKB to TBIT on December 15, 2026.
Notice of termination given to ARK Investment Management on October 16, 2026
Termination effective December 22, 2026
On December 15, 2026, the Sponsor intends to rename the Trust to 21Shares Bitcoin ETF
AmeriServ Bank, a unit of AmeriServ Financial, has transitioned its investment services program to the Ameriprise Financial Institution Group, according to an October 22, 2026 press release filed with the SEC. The filing states that the bank's financial advisors help clients manage approximately $525 million in assets across Pennsylvania and Western Maryland. The filing does not report financial results or a dollar value for the transaction.
Investment services program transitioned to Ameriprise Financial Institution Group (AFIG), announced October 22, 2026
Financial advisors help clients manage approximately $525 million in assets across Pennsylvania and Western Maryland
Company reports $2.8 billion of customer assets under management and administration, and total assets of $1.45 billion as of September 30, 2026
Chairman J. Michael Adams, Jr. said the partnership is designed to grow the AmeriServ Wealth Management complex
Tucows subsidiary Ting Fiber agreed on October 21, 2026 to transfer its dark fiber lease with Colorado Springs Utilities to Google Fiber Colorado, LLC, with closing expected March 31, 2027. Tucows' parent guaranty of Ting's lease obligations, which the company previously estimated at about $322.8 million for the remaining term, is expected to terminate by the end of April 2027, and the company describes the move as part of its ongoing strategic process for Ting.
Ting Fiber entered the Novation Agreement with Google Fiber Colorado, LLC on October 21, 2026; closing is set for March 31, 2027, subject to customary conditions.
Tucows' Parent Guaranty is expected to terminate by the end of April 2027, after closing and certain post-closing obligations to Colorado Springs Utilities are satisfied.
Ting's aggregate lease payment obligations were estimated at approximately $322.8 million for the remaining term, per the Form 10-Q for the quarter ended June 30, 2026.
Ting will keep serving Colorado Springs customers through a transition to be completed no later than June 30, 2027; customers need take no action now.
Edible Garden entered a Produce Supply Agreement with Caney Fork Farms, LLC, effective October 15, 2026, for purchasing and reselling fresh produce for its core herb business. The contract sets fixed pricing through January 31, 2027, runs until October 15, 2028, and gives the company a right of first offer on related supplier opportunities.
Agreement dated October 16, 2026, effective October 15, 2026, with Caney Fork Farms, LLC
Fixed pricing through January 31, 2027; later annual increases capped at the lesser of the Producer Price Index change or 10%
Company must pay for planted products and packaging if it cuts weekly orders below guaranteed minimums with less than 90 days' notice
Term runs to October 15, 2028, with automatic one-year renewals unless either party gives 60 days' notice
Reborn Coffee entered a Master Product Supply Agreement with Visvita Corporation dated October 11, 2026, under which it will sell aloe vera beverages and other products on a non-exclusive basis through purchase orders. The parties agreed to try to reach a $30 million minimum business volume in the first contract year, and an initial $2 million purchase order was signed; the filing does not report financial results. Shareholders should note that the $30 million figure is a target and each order is binding only after the company accepts it.
Agreement dated October 11, 2026; supply is non-exclusive, and purchase orders bind only after written acceptance by the company.
Parties agreed to try to achieve a $30 million business volume minimum in the first contract year; an initial $2 million purchase order was entered into.
The company sets supply prices with a profit margin on each order; payment is due 60 to 120 days after the order is placed with the Korean manufacturer.
Term is two years from October 11, 2026, renewing yearly unless notice is given at least 60 days before expiration; Visvita's president, Michael Aminpour, also serves as the company's Head of Global Sales Advisory.
First Breach announced that its drone prototype reached 161 km/h (100 mph) in flight testing without a payload, the maximum groundspeed the FAA permits under Part 107 without a waiver, and that it is pursuing FAA authorization to test faster. The filing also notes a Chief Revenue Officer presentation at a October 20 investor conference. The filing contains no revenue, earnings, or guidance figures, so it gives shareholders no financial results to judge.
Prototype reached 161 km/h (100 mph) in flight testing without a payload, above the 120 km/h (74 mph) speed in prior published specifications.
Company is obtaining FAA waivers to test above the Part 107 limit; no waiver timing was given.
Initial prototype completion is targeted for Q4 2026 and scaled production for Q2 2027, with capacity above 2,500 drones per week.
Chief Revenue Officer Ken Leith presented at the LD Micro Main Event on October 20, 2026.
Tron Inc. said its Super Representative node has risen to No. 1 in current rankings, with approximately 3.71 billion delegated TRX tokens as of October 21, 2026. The company also intends to operate multiple nodes to broaden recurring on-chain revenues, though the release gives no financial results or revenue figures.
SR node ranked No. 1 with approximately 3.71 billion delegated TRX tokens as of October 21, 2026
Rise follows official SR election earlier in October 2026
Company intends to operate multiple nodes to expand recurring on-chain revenues
Release cites TRON network stablecoin activity of over $94 billion, more than 50% of global USDT circulation
NextTrip, Inc. announced a joint venture agreement with The Travel Agent Next Door Inc., a Canadian travel agency network, to connect Canadian viewers of JOURNY TV with travel booking through JOURNYGO Travel. NextTrip will generate travel inquiries and receive a share of remaining booking commissions, while the partner handles advisor service, booking and fulfillment. The filing gives no financial terms, revenue figures or launch date, so the near-term effect on shareholders is unquantified.
Partner network has 1,850 agents and C$620 million in annual travel sales
NextTrip receives a share of booking commissions remaining after advisor compensation or specified customer service costs
Launch timing and specific program offerings will be announced as implementation progresses
Supplier sponsorship support has not been committed under the agreement
Anavex said it has finished clinical conduct of two pharmacology studies of blarcamesine, an ADME study and a DDI study, both in healthy volunteers. The company said full safety and pharmacokinetic data analysis is still ongoing, and it expects the data to support its FDA-focused development program.
DDI study: last participant completed at the end of September 2026; 65 participants, all received 30 mg
ADME study: last participant completed in mid-October 2026; 8 participants, all received 30 mg
Preliminary observations show no serious adverse events reported; full analysis ongoing
FDA meeting planned for November 2026 on adding pediatric participants to the Rett syndrome Phase 3 study
Deep Fission (Nasdaq: FISN) said it signed a Master Energy Purchase Agreement with the Great Plains Development Authority for a planned commercial nuclear project at the Great Plains Industrial Park in Parsons, Kansas. The 25-year agreement converts a December 2025 letter of intent into a binding contract, but it is subject to regulatory approvals and other conditions, and it has no minimum purchase obligation, so the filing does not quantify its financial effect.
Binding 25-year Master Energy Purchase Agreement with the Great Plains Development Authority, replacing the December 2025 letter of intent
Initial phase of 150 MW with a target commercial operation date of September 30, 2028; later phases could reach 2,000 MW
No minimum purchase obligation; electricity purchases depend on tenant demand and are subject to regulatory approvals
The filing reports no revenue or financial figures for the agreement
Freenome announced on October 20, 2026 the launch of SimpleScreen Lung, a laboratory-developed lung cancer blood test, and an offering that lets eligible patients be screened for lung and colorectal cancer through a single blood draw. The filing reports clinical validation data but no financial results, guidance, or financial terms, so the announcement gives shareholders no direct read on revenue or profit.
SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value in an independent cohort of 172 lung cancer cases and 436 controls.
SimpleScreen Lung has not been reviewed or cleared or approved by the FDA; the SimpleScreen CRC test is FDA-approved for adults 45 and older at average risk.
Abbott has exclusive U.S. commercial rights to SimpleScreen CRC when it is ordered as a standalone test.
The launch was announced October 20, 2026, and the company will show the portfolio at the FMX conference in Nashville, October 20 to 24.
Kartoon Studios said it has contracted with Walmart Marketplace to sell consumer products, such as toys, books and apparel from licensees, based on its HUNDRED ACRE WOOD animated series. The arrangement starts January 18, 2027, and the company expects matching products to be available on Walmart Marketplace at the same time as the series release. The filing gives no financial terms, so its effect on revenue or earnings cannot be measured from this document.
Walmart Marketplace will sell consumer products including toys, books and apparel from licensees.
Products are based on the HUNDRED ACRE WOOD series, which is based on A.A. Milne's Winnie the Pooh.
The arrangement begins January 18, 2027.
The company expects products to be available on Walmart Marketplace concurrent with the series release; no financial terms were disclosed.
Quoin Pharmaceuticals announced the online publication of a peer-reviewed paper introducing its investigational lotion QRX003 and a single pediatric compassionate-use case report. The filing presents single-patient observations only and does not report new trial results, revenue, or financial measures, so the announcement is clinical-awareness news rather than a financial result.
Paper published online October 13, 2026 in Dermatology and Therapy and announced October 20, 2026
Single pediatric patient's IGA score improved from 4 (severe) to 1 (almost clear) after six weeks and reached 0 by eight months
Company expects to complete recruitment of 20 participants in Phase 2/3 study CL-QRX003-004 by end of 2026 and report topline data in Q2 2027
Clene Inc. entered into a subaward amendment on October 15, 2026, for the fourth year of a four-year $45.1 million NIH grant, with New York University receiving up to $7.2 million for the period September 1, 2026 to August 31, 2027. The grant supports an Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis, and the other terms of the subaward remain unchanged. The filing is an administrative funding update under an existing grant rather than a change in the company's financial results or guidance.
Subaward amendment dated October 15, 2026, for up to $7.2 million with New York University
Covers the period September 1, 2026 to August 31, 2027
Part of a four-year, $45.1 million NIH grant announced October 5, 2023
Other subaward terms from the March 16, 2026 filing remain in effect
3M entered into an expanded strategic commercial relationship with a subsidiary of Amazon.com, Inc. and issued that subsidiary a seven-year warrant to buy up to 3,162,015 shares of 3M common stock at $164.89 per share. The filing says 85% of the warrant shares vest based on Amazon payments for optical connectivity and other Data Center products, with full vesting once cumulative payments reach $6 billion. For shareholders, the warrant adds potential dilution, though its vesting ties it to future purchases.
Warrant covers up to 3,162,015 shares of 3M common stock over seven years
Exercise price is $164.89 per common share
85% of warrant shares vest with Amazon payments for optical connectivity and other Data Center products; full vesting at $6 billion in cumulative payments
Remaining warrant shares vest subject to event-based milestones not specified in the filing
LQR House said its subsidiary YHC AI Limited signed a one-year agreement to procure up to $3 million in AI computing resources powered by OpenAI technologies for Fusion Five Continents Securities. The filing reports no financial results or guidance, and the amount ultimately payable depends on Fusion Five's deployment requirements and usage during the contract term.
One-year agreement by subsidiary YHC AI Limited to procure up to $3 million in AI computing resources powered by OpenAI technologies.
Resources support AI-driven research, quantitative analytics and portfolio optimization at Fusion Five Continents Securities, including access to the latest GPT models available in Singapore.
A $30,000 deposit has been paid; the remaining amount payable depends on Fusion Five's usage during the contract term.
Disclosed under Item 7.01 with press release Exhibit 99.1 dated October 19, 2026; no earnings or guidance included.
ArriVent BioPharma announced the publication of Phase 1b FURTHER trial results for its drug firmonertinib in the journal Cancer Cell, covering patients with EGFR PACC-mutant non-small cell lung cancer. The filing is a clinical data and publication update with no financial results, guidance, or financing terms, so its direct effect on shareholders is not quantified in the filing.
Reported confirmed overall response rates of 43% (160 mg) and 68% (240 mg) in front-line EGFR PACC-mutant NSCLC, per blinded independent central review.
Reported 11.1- and 16.0-month median progression-free survival at the two doses.
The company continues to enroll patients in its global Phase 3 ALPACCA trial.
NioCorp's majority-owned subsidiary Elk Creek Resources signed an Offtake Agreement with Traxys North America on October 13, 2026, replacing prior ferroniobium and scandium offtake agreements with Traxys. The deal gives Traxys take-or-pay purchase rights on 50% of annual ferroniobium output and exclusive marketing rights for 100% of other Elk Creek products, which matters to shareholders because it sets the sales framework for the project's planned output.
Agreement dated October 13, 2026, between Elk Creek Resources and Traxys North America LLC
Traxys to buy 50% of annual ferroniobium production on a take-or-pay basis, or 3,700 metric tonnes per year at Traxys' election
Term of 15 years from the Commercial Production Date, followed by two automatic one-year renewals
Either party may terminate if the Export-Import Bank of the United States has not given final approval of senior debt financing by December 31, 2027
RYTHM's subsidiary VCP IP Holdings amended its trademark license with GTI Core, a Green Thumb subsidiary, adding the Señorita brand to the licensed intellectual property. The base licensing fees rose by $250,000 per year, and GTI Core's rights are limited to state-regulated dispensary channels, with the company holding exclusive rights outside them if legally permitted. Because Green Thumb owns about 32% of RYTHM's common stock, the related-party license change is relevant to shareholders.
Amendment No. 2 dated October 13, 2026 adds the Señorita brand to the license granted to GTI Core, LLC.
Base licensing fees under the August 2025 License Agreement increased by $250,000 per year.
Exclusive rights outside state-regulated dispensary channels go to RYTHM and its affiliates if legally permitted and consistent with Nasdaq listing standards.
Green Thumb is an indirect owner of about 32% of RYTHM's outstanding common stock.
Tianci International subsidiaries agreed on October 12, 2026 to have Linknex Limited, a Hong Kong company, build an enterprise AI integration platform for their businesses. Payment will combine $146,700 in cash with 180,000 newly issued Tianci common shares, to be issued within twenty business days after the shares are listed on Nasdaq, so the deal adds a share issuance that could dilute existing holders.
Agreement dated October 12, 2026 between subsidiaries RQS United Group Limited and Roshing International Co., Limited and Linknex Limited
Consideration: $146,700 in cash plus 180,000 shares of Tianci common stock
Shares to be issued within twenty business days after listing on Nasdaq
A Statement of Work with scope, milestones and acceptance criteria is yet to be signed
As of October 13, 2026, United States Natural Gas Fund, LP amended its ISDA 2002 Master Agreement with Société Générale, lowering the Total Net Assets Decline Event termination trigger from $1.5 billion to $200 million. The company says the reduced threshold reflects its performance and is intended to ensure the trigger is not hit absent a credit event.
Amendment dated as of October 13, 2026 to the ISDA 2002 Master Agreement originally entered into June 13, 2022
TNA Decline Event Additional Termination Event threshold reduced from $1.5 billion to $200 million
Full agreement filed as Exhibit 10.16 and incorporated by reference
Crescent Biopharma said in an October 15, 2026 press release that it has enrolled patients in chemotherapy combination cohorts of its ASCEND trial for CR-001, and that the FDA has cleared its CR-002 ADC for a Phase 1/2 trial. The filing gives timing for several clinical data readouts but reports no revenue, earnings, or financial results, so it is a pipeline update rather than a financial report for shareholders.
Initial CR-001 monotherapy data from ASCEND expected in the first quarter of 2027, covering more than 125 patients
Chemotherapy combination cohort data anticipated in mid-2027; Phase 3 trials of CR-001 planned to start in early 2028
CR-002 received FDA IND clearance in October 2026; APOLLO Phase 1/2 trial planned to start in the fourth quarter of 2026, with initial data in the second half of 2027
New America Acquisition I Corp. entered into an Administrative Services Agreement with Dominari Holdings Inc., an affiliate of certain officers and directors, for office space and administrative services at $20,000 per month. On the same day, the company's earlier administrative services agreement with its sponsor, New America Sponsor I LLC, was terminated under a Termination and Release Agreement.
New agreement with Dominari Holdings Inc. dated October 15, 2026, at $20,000 per month
Fee runs until the earlier of an initial business combination or the company's liquidation
Prior administrative services agreement with New America Sponsor I LLC, dated December 3, 2025, terminated October 15, 2026
iPower Inc. said its subsidiary, iPower AI LLC, received a customer-signed, non-binding letter of intent for a five-year AI equipment services and management relationship. The company says the deal would support its shift toward AI infrastructure and services, but the terms are not final and the filing states the fee figures are not committed revenue, backlog, profit or 2027 revenue guidance.
The customer plans an initial fleet of 48 AI computing units, expanding to about 396 units during 2027.
At a proposed fee of $4,608 per unit per month, the full fleet would represent up to $21.90 million annualized over five years.
The initial 48 units would represent about $2.65 million in annualized fees.
The LOI is non-binding and subject to a definitive services agreement; the filing says there can be no assurance one will be executed.
Edesa Biotech reported that the FDA has cleared its Investigational New Drug application for a Phase 2 study of EB06 in vitiligo, allowing the company to expand patient recruitment to the United States. Patient recruitment is already underway in Canada, and the company anticipates topline data in the fourth quarter of 2027. The filing describes a clinical milestone, not a financial result, and the safety and efficacy of EB06 remain subject to clinical evaluation.
FDA cleared the IND application for the Phase 2 study of EB06 in vitiligo, announced October 15, 2026
Study will enroll up to 80 adults with moderate-to-severe nonsegmental vitiligo, randomized 1:1 to EB06 or placebo
First U.S. investigational sites are expected to begin enrolling subjects next quarter
Topline data anticipated in the fourth quarter of 2027
Quantum Leap Energy, a wholly owned subsidiary of ASP Isotopes, signed a Heads of Agreement with South Africa's Nuclear Energy Corporation (Necsa) that sets a binding commercial framework for a joint venture to produce High-Assay Low-Enriched Uranium at Necsa's Pelindaba site. The filing gives no financial value or capital commitment for the venture, so its effect on shareholders is not quantified.
QLE would hold approximately 80% of the joint venture and lead operations and capital arrangements; Necsa would hold approximately 20%.
The joint venture would develop, finance, construct, commission, own and operate a test bench and commercial-scale HALEU facility at Pelindaba, South Africa.
QLE has offtake for the expected HALEU output through supply agreements with TerraPower.
South Africa's Ministry of Electricity and Energy approved QLE's source material and equipment activities at Pelindaba in July 2026.
Jasper Therapeutics said it has completed enrollment of the IgA nephropathy cohort of its Phase 2 basket study of vensobafusp alfa (KP104), with 18 patients enrolled in stage 1. The company expects initial interim data from the IgAN cohort by year-end 2026 and has added an FSGS cohort, with first dosing anticipated in the first quarter of 2027. The filing contains no financial results, so the update is a clinical development milestone rather than a change in reported financial measures.
Enrollment completed in the IgAN cohort: 18 patients across 3 cohorts (Q2W, Q4W and Q8W maintenance, six patients each)
Initial interim data from the IgAN basket study expected by year-end 2026
FSGS expansion cohort added, with first patient anticipated to be dosed in the first quarter of 2027
On October 9, 2026, Venture Global's subsidiary VGLNG signed frame agreements with GE Vernova, Baker Hughes and GE Grid for power generation and grid equipment, covering up to 16 power islands and 21 power island projects with deliveries through 2034. If the company proceeds with all purchase orders, the combined amount payable would be approximately $17.2 billion, subject to adjustment, but the company has no binding purchase obligations beyond reservation fees until it places individual orders. The filing says the equipment can support LNG export projects and planned data center developments, and that the company expects to place its first power island purchase order by the end of 2026.
Power Frame Agreement with GE Vernova and Baker Hughes, signed October 9, 2026, covers up to 16 power islands with deliveries through 2034 at the latest.
Grid Frame Agreement with GE Grid, signed October 9, 2026, covers power transformer and gas insulated switchgear for up to 21 power island projects.
Combined amount would be approximately $17.2 billion if all purchase orders proceed, subject to adjustment based on specified criteria.
No binding purchase obligations beyond reservation fees until purchase orders are entered; first power island purchase order expected by end of 2026.
Establishment Labs, through its subsidiary ELSA, signed Amendment No. 3 to its Master Supply Agreement with NuSil Technology LLC, effective January 1, 2027. The amendment extends the initial term from December 31, 2026 to December 31, 2031, with automatic one-year renewals for up to five terms unless either party gives notice. The filing does not disclose financial terms, so its effect on shareholders is limited to supply continuity and contract terms.
Initial term of the supply agreement extended from December 31, 2026 to December 31, 2031
Automatic one-year renewals for up to five successive terms unless either party gives notice by December 31 before expiration
Amendment also covers medical-grade silicone supply, payment terms, business continuity, intellectual property and pricing provisions
Exascale Labs agreed to sell 12 NVIDIA HGX B300 GPU servers, with network equipment, deployment and 36 months of IT operation services, to a U.S. subsidiary of Taiwan's Sunonwealth Electric Machine Industry for a total contract value of $8,208,000 before import duties and taxes. The filing does not state the effect on the company's revenue or profit, and delivery depends on a 30% down payment, chip manufacturer approval and export and import authorizations.
Total contract value is US$8,208,000, exclusive of import duties and taxes.
Buyer is Sunon Inc., a California subsidiary of Sunonwealth Electric Machine Industry Co., Ltd. (TWSE: 2421).
Payment: 30% down payment within three days of the buyer's purchase order, with the remaining 70% due five business days after shipment-readiness notice.
Agreement dated October 8, 2026, entered October 9, 2026; the filing was dated October 15, 2026.
Riot Platforms entered a custody agreement with BitGo Bank & Trust, which will hold its digital assets and cash, replacing NYDIG Trust Company as custodian. The filing describes segregated accounts, a monthly fee based on average custodied asset value, and a one-year renewable term, but it does not disclose the dollar amount of assets or fees.
Agreement dated October 7, 2026, amended October 14, 2026; NYDIG Trust's custodial agreement terminates when assets transfer to BitGo Bank & Trust
Assets to be held in segregated accounts, with the company retaining title; the company pays a monthly fee based on average asset value
Initial one-year term with automatic renewal; either party may give 60 days' notice of non-renewal; company may terminate early on 14 days' notice with no termination fee
Flyte Aviation announced a multi-year partnership under which it is named the Official Private Aviation Partner of the Philadelphia 76ers. The filing furnishes the October 14, 2026 press release and includes no financial results, deal value, or payment terms, so the financial effect on shareholders is not quantified.
Multi-year partnership with the Philadelphia 76ers announced October 14, 2026
Flyte named the Official Private Aviation Partner of the team
Planned activities include digital and social media, premium hospitality, fan engagement, and a "Halftime Flyte Challenge" giving selected fans a chance to win a private flight
Filing does not disclose contract value or financial terms
Tecogen Inc. issued a press release on October 14, 2026 featuring a customer testimonial from Cloudsmart, Inc., a Connecticut data center operator that uses the company's InVerde cogeneration system to generate its own power. The filing contains no financial results, guidance, or deal terms, so it gives shareholders no new financial figures; it does show a customer reporting lower electric bills.
Cloudsmart CEO Robyn Sullivan says the InVerde unit has run for a few months and the company cut its electric bills substantially.
Tecogen CEO Abinand Rangesh says the testimonial is a proof point for converting the company's data center pipeline to orders.
The filing gives no revenue, earnings, order, or dollar savings figures.
Pulse Biosciences announced on October 14, 2026, a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates. The center is now treating patients with the nPulse Vybrance Percutaneous Electrode System, and the two parties will collect real-world outcomes data and work on formal clinical studies of the system for benign thyroid nodules. The filing does not disclose financial terms, so the partnership's effect on Pulse Biosciences' revenue is not quantified.
Partnership announced October 14, 2026, with the Clayman Thyroid Center and its affiliates in Tampa, Florida
The center is now treating patients with the Vybrance System as part of the company's controlled market development strategy
The center is the only site in the Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules
Collaboration covers real-world outcomes collection and formal clinical studies; the filing gives no financial terms
Fermi Inc. posted a fact sheet on its website describing a binding 15-year phase one lease with TensorWave at Project Matador, with contracted revenue of $6.5 billion over the initial term. The lease is backed by credit support from AMD, which begins once construction is complete and rent starts, and the company says it supports project financing.
Phase one covers 222 MW total power capacity and 156 MW critical IT capacity, with phased delivery starting Q4 2027 and completing early 2028.
Estimated phase one project-level NOI margin is approximately 75% to 80%; the company says this excludes variable power charges passed through to the tenant.
AMD credit support is signed; the company notes AMD's obligations start only after construction is complete and rent commences.
First Breach said on October 13, 2026 that its proprietary drone prototype completed a fully autonomous flight from takeoff to landing without manual pilot input, and that it is porting the flight stack to PX4. The filing also reiterates targets of initial prototypes in Q4 2026 and scaled production in Q2 2027, but contains no financial results, so the update gives shareholders development progress rather than measurable revenue or profit.
Prototype completed its first fully autonomous mission on October 13, 2026, per Exhibit 99.2
Company continues to target initial prototypes in Q4 2026 and scaled production in Q2 2027, with capacity above 2,500 drones per week
On October 8, 2026, the company announced an expanded recruitment initiative for ammunition production and drone operations in Hagerstown, Maryland
bioAffinity Technologies announced it will present new research on investigational sputum-based tests that measure lung inflammation and protein biomarkers, including targets of asthma and COPD biologic drugs, at the CHEST 2026 meeting. The tests are not validated, not cleared or approved by the FDA, and not available for clinical or diagnostic use, so the update is a research milestone rather than a financial or commercial event.
Poster titled "Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma" is scheduled for October 20, 2026, 1:45-2:30 p.m. at the Phoenix Convention Center.
Chief Medical Officer Gordon Downie will lead a discussion at CHEST 2026 on October 21 at 12:30 p.m. in Learning Theater 4.
The tests are investigational, not validated, not FDA cleared or approved, and not currently available for clinical or diagnostic use.
The filing states no financial results, revenue or guidance figures.
Apimeds subsidiary MindWave Innovations signed a two-year Master Service Agreement with BlockAssure Inc. to build, deploy and operate AssureChain, a dedicated subnet of MindChain for recording BlockAssure's insurance and reinsurance processes on-chain. The filing does not disclose a dollar value for the fixed development fee, and operate and maintenance fees are still to be agreed, so the financial effect on shareholders cannot be measured from the filing.
Agreement took effect October 4, 2026; it renews automatically for one-year periods unless either party gives 90 days' notice.
Consideration includes a fixed development fee payable in quarterly installments, with no dollar amount stated in the filing.
MindWave is to receive an allocation of AssureCoin equal to 20% of its total supply, delivered when the token is created.
Development is planned over four quarters against agreed milestones, with BlockAssure acceptance-testing each module.
Bluejay Diagnostics said on October 13, 2026 that it has completed establishing a manufacturing site for Symphony cartridges, ahead of an October 23, 2026 contractual deadline under its amended license agreement with Toray Industries. The filing states the milestone is a step toward regulatory submission and potential commercialization, but it reports no revenue, earnings or guidance figures.
Milestone completed ahead of the October 23, 2026 deadline in the amended Toray Industries license agreement.
Manufacturing site is SanyoSeiko Co., Ltd. in Japan; ALURIS Sciences in the United States is a complementary manufacturing partner.
The Symphony IL-6 Test has not been cleared or approved by the FDA and is not available for commercial clinical use in the United States.
The filing contains no financial results, guidance or dollar figures.
Phio Pharmaceuticals announced on October 13, 2026 that it successfully released its first commercial-scale cGMP batch of PH-762 drug substance. The batch will move on to final drug product steps for the planned Phase 2b clinical study, which the company expects to start in the first quarter of 2027. The filing reports an operational milestone and includes no financial results.
Batch was manufactured to established specifications and confirmed by a Certificate of Analysis and Certificate of Compliance
Planned Phase 2b clinical study of PH-762 is expected to begin in the first quarter of 2027
CEO Robert Bitterman said the work began about 16 months ago and is intended to mitigate key development and manufacturing risks
Ondas Inc. and Palantir Technologies announced on October 12, 2026 the formation of Regna AI, a standalone private company that will build fine-tuned open-weight AI models for governments and defense partners. Ondas is initially the sole owner and will be Regna AI's first customer, and the filing says Ondas expects its operating expenses for sovereign AI development to move to Regna AI over time. The filing gives no financial terms, funding amounts, or revenue figures for the new company.
Regna AI formed October 12, 2026 with Palantir; initially wholly owned by Ondas
Ondas will serve as Regna AI's initial customer, with deployments expected over the coming months
Ondas expects to engage financial partners over time to support Regna AI as an independent company
No dollar figures for investment, revenue or ownership changes are disclosed in the filing
SAB Biotherapeutics announced that the FDA granted Fast Track designation to SAB-142, an immunotherapy being developed for new-onset Stage 3 type 1 diabetes. The designation is intended to facilitate development and expedite review for serious conditions with unmet medical need, and the filing says SAB-142 is in a registrational Phase 2b study with topline data anticipated in 2H 2027.
FDA granted Fast Track designation to SAB-142 for new-onset Stage 3 type 1 diabetes, announced October 13, 2026
SAB-142 is being evaluated in the registrational Phase 2b SAFEGUARD study, with enrollment expected to be completed in Q4 2026
Topline data from the SAFEGUARD study are anticipated in 2H 2027
The filing does not disclose financial figures related to the designation
Electra AI, which is merging with SPAC Iron Horse Acquisition II Corp. (IRHO), announced that Westbrook Racing by Visit Angola, a UIM E1 World Championship team, selected Electra as its Official Battery Intelligence Partner under a three-year agreement starting with the 2026 season. The filing is a commercial announcement that contains no financial results, and the pending business combination remains subject to shareholder approval and other conditions.
Westbrook Racing by Visit Angola selected Electra AI's AI Brain for Batteries platform and Race Boost Optimizer module under a three-year agreement beginning with the 2026 season.
The filing does not disclose contract value or financial terms.
Electra AI and Iron Horse have a Business Combination Agreement dated April 21, 2026; the combined company is expected to list on Nasdaq under the ticker AIBR in the second half of 2026.
The business combination will be submitted to IRHO shareholders, and no record date has been set in the filing.
Quanome Technologies said its subsidiary XDT entered a Master Services Agreement and initial Order to provide dedicated AI computing capacity to an enterprise customer. The initial 60-month order has a total commitment value exceeding $100 million, and service is expected to start in about two months, subject to service-start conditions.
Initial Order has a 60-month term from the service-ready date and a total commitment value exceeding $100 million
XDT expects service to commence within approximately two months, subject to service-start conditions
Quanome also agreed to buy 32 additional GPU server units for approximately US$18.8 million, for delivery to a designated U.S. data center
Press release dated October 8, 2026; the filing does not report revenue or earnings figures for the deal
Marwynn Holdings entered into a memorandum of understanding with OmniX Technologies Pte. Ltd. on October 8, 2026, to evaluate cooperation in AI and high-performance computing, RWA and securities infrastructure, and regional market entry. The filing states that the MOU is largely nonbinding, sets no price or investment amount, and does not establish contracted revenue, so shareholders have no committed financial impact from it yet.
MOU dated October 8, 2026; the full text is filed as Exhibit 10.1.
Indicative four-phase evaluation: mobilization in the first 30 days, assessment in days 31 through 120, potential pilots in months five through nine, and potential definitive agreements in months ten through eighteen.
MOU has no price, fee, revenue share, investment amount, or minimum purchase commitment, and does not establish contracted revenue for the Company.
MOU runs 18 months and can be terminated on 60 days' written notice; preferred-partner obligations can be ended on 30 days' written notice.
Quantum-Si said it has demonstrated detection of 19 amino acids in its Proteus development program and is now working to deploy that capability into a developmental sequencing kit for R&D use. The company reaffirmed its target of demonstrating detection of all 20 amino acids by year-end 2026 and its planned commercial launch of Proteus in the second quarter of 2027, but the filing contains no financial results.
Detection of 19 amino acids demonstrated in the Proteus development program, announced October 8, 2026
Previously, a developmental kit detecting 18 amino acids was presented at the 2026 World HUPO Congress
Company target is detection of all 20 amino acids by year-end 2026
Proteus commercial launch is planned for the second quarter of 2027
Shoulder Innovations announced a limited user release of the InSet Go, its next-generation glenoid implant, after the first surgical case was completed at University Hospitals Cleveland Medical Center. The filing contains no financial figures, and the company said it expects a full commercial introduction over the coming quarters, so the news is an early step in the product's rollout.
First surgical case using InSet Go was performed by Robert Gillespie, MD, at University Hospitals Cleveland Medical Center, Cleveland, OH
The company says InSet Go reduces surgical steps and offers the potential for reduced procedure times
Full commercial introduction is expected over the coming quarters, according to CEO Rob Ball
The filing reports no revenue, earnings or guidance figures
Editas Medicine said it received approval to start the Phase 1/2 Strive trial of its experimental gene editing medicine EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia, and submitted the trial for review in New Zealand. The filing states that the company expects to report initial safety and tolerability data in the first quarter of 2027, with topline safety and efficacy data later in 2027, so the program is still at an early clinical stage with no financial results attached.
Trial received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration
Trial has been submitted for review in New Zealand; patients in both countries would be eligible to enroll if approved there
Initial safety and tolerability data expected in the first quarter of 2027
New preclinical data on LDL-C reduction will be presented at the AHA Scientific Sessions on November 8, 2026
On October 5, 2026, BioNexus Gene Lab Corp. agreed to an exclusive Malaysian healthcare licence to Ruanyun Edai Technology's CogniAI document-intelligence platform, with closing still pending. The company will issue a total of 560,000 common shares, about 16.0% of its outstanding shares after issuance, with no cash payment, which shareholders would bear as dilution. The filing states that BioNexus has not been awarded any government contract and that closing depends on technology acceptance, due diligence and approvals.
Share consideration: 410,000 shares for a stated US$3.5 million licence fee, plus 150,000 shares for 500,000 RYET ordinary shares, totaling 560,000 shares, or about 16.0% of outstanding common shares after issuance.
Royalty: RYET receives 10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee.
Closing: either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
Government work: BioNexus has not been awarded any government contract, and any public-sector work would depend on government procurement.
BioCardia announced that it will present a scientific poster on the design of its CardiAMP HF II trial at the Heart Failure Society of America Annual Scientific Meeting in Phoenix, Arizona, October 9 to 12, 2026. The filing says FDA recently agreed that the ongoing trial may be sufficient to support FDA approval, but it contains no financial results, and the event is a scientific presentation rather than a financial or regulatory decision.
Poster presentation at HFSA Annual Scientific Meeting in Phoenix, Arizona, October 9 to 12, 2026
Presentation covers the design and scientific support for the CardiAMP HF II Study in ischemic heart failure with reduced ejection fraction
FDA recently agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval
The filing reports no revenue, earnings or guidance figures
AIB Data Centers issued a shareholder letter from CEO Jerry Tang highlighting a 12-year agreement with Nebius for 50 MW of critical IT capacity at its CLT1 campus, plus a Texas acquisition that raised contracted utility power from 65 MW to about 120 MW. The company said it does not currently anticipate needing corporate-level common equity to fund CLT1, relying instead on customer prepayments and project-level debt or preferred equity.
Nebius agreement: 12-year initial term for 50 MW of critical IT capacity at CLT1, with two potential five-year renewals
Contracted utility power increased from 65 MW to approximately 120 MW after a Texas acquisition
Company does not currently anticipate requiring corporate-level common equity to fund CLT1 development
The filing contains no revenue, profit or financial figures for the period
TaoWeave said its portfolio company Manako Labs Ltd. has gone live commercially with Avia Thévenin-Ducrot, a French fuel retail group, across a first wave of 124 unmanned Avia Xpress stations. The filing says this is a commercial deployment by an enterprise operator, but it gives no revenue, licensing fee or financial figures tied to the deal, so its effect on TaoWeave's results is not quantified.
Manako Labs' Vision Agents run around the clock across a first wave of 124 unmanned Avia Xpress stations in France.
Avia Thévenin-Ducrot named Manako its lead Physical AI design partner.
TaoWeave invested in Manako in June 2026 and holds North American commercialization rights to its platform.
The filing does not disclose any revenue or financial amounts from the deployment.
BKV's subsidiary signed an equipment supply contract on October 2, 2026, for turbines and related equipment for a prospective Texas power project, at an aggregate price of about $800.0 million. The hyperscaler that backstops about 90% of near-term payments is also the intended offtaker, and BKV may terminate the contract without further payment obligations if offtake terms are not agreed by March 31, 2027.
Aggregate price of about $800.0 million, including $80.0 million in reservation fees previously paid that are credited against the price.
About $200.0 million is due on or before March 31, 2027, with about 90% of that covered by a backstop agreement with an investment-grade hyperscaler.
Equipment deliveries are scheduled between September 2028 and May 2029; BKV may terminate if offtake arrangements are not reached by March 31, 2027.
Health Canada approved TLANDO, a Lipocine oral testosterone product, for testosterone replacement therapy in adult males, announced October 7, 2026. The approval is held through licensing partner Verity Pharma, which plans a Canadian launch by the end of 2026 and holds exclusive North American commercial rights.
Approval covers adult males with conditions tied to testosterone deficiency or absence (male hypogonadism).
Verity Pharma holds exclusive commercial rights to TLANDO in North America and plans a Canadian launch by the end of 2026.
The filing cites more than 700,000 annual TRT prescriptions in Canada, but gives no sales or revenue projection for TLANDO in Canada.
Calisa Acquisition Corp, a special purpose acquisition company, filed an 8-K furnishing a GoodVision AI press release on two U.S. collaboration agreements, with TDTC and HOP Global, plus an investor presentation. GoodVision is the target of a pending business combination with Calisa, so these agreements relate to the company shareholders would own if the merger closes; the filing says the agreements do not guarantee any revenue.
TDTC agreement targets a Texas Site No.1 AI Factory with 2.4 MW of confirmed power, expandable to up to 15 MW within one year
GoodVision estimates the 15 MW TDTC project could represent approximately $210 million in annual revenue potential, based on internal assumptions
HOP Global pilot would scale to 100 nodes, about 5 MW, with an estimated $36 million in annual revenue potential, also based on internal assumptions
The filing states neither collaboration requires a binding transaction and that the estimates are preliminary and unverified
SRX Global said it has committed $1.5 million to launch a family of actively managed exchange traded funds through its EMJX platform, in partnership with Kupa AI. The company also intends to distribute its holdings from the ETF launch directly to shareholders, with timing and record date to be announced later. The filing gives no financial results, so the near-term effect on shareholders is not quantified.
SRX committed $1.5 million to launch the ETF family, in partnership with Kupa AI
The first ETF is expected to be available to retail and institutional investors in the first quarter of 2027
The first fund will use a digital asset hedging strategy powered by EMJX's AI-driven regime model
SRX intends to dividend its ETF holdings to shareholders; timing and record date to be announced later
NOMAD Power Solutions announced a 2026 demonstration tour that will take its Voyager and Voyager Falcon mobile battery energy storage systems to 26 stops across three regional roadshows in October and November. The filing is a marketing and customer-outreach announcement and contains no financial results, guidance, or quantified sales outcomes, so it gives shareholders no measure of the tour's financial effect.
The tour runs in three roadshows: Mountain West (October 6-8, five stops), Northeast (October 13-26, 14 stops), and Southwest (November 2-16, seven stops).
The Voyager 1.0 unit provides 1 MW of power and 1.3 MWh of energy-storage capacity, per the release.
The company states that there is no guarantee the tour will result in new customers.
PowerCompute's subsidiary US Digital Mining Mississippi LLC entered into a new Industrial Power Contract with Columbus Light and Water on September 30, 2026, replacing its prior power contract for the Columbus, Mississippi data center. The company says contracted power at the site rose from 8.5 megawatts to 11 megawatts and that it was not assessed a Tennessee Valley Authority capacity commitment charge, which applies to new or expanded data center load above the first five megawatts. The filing includes no revenue, earnings or cost figures, so the financial effect rests on management's statements in the press release.
Contract entered into September 30, 2026; the press release says it took effect October 1, 2026, while the exhibit lists an effective date of September 16, 2026
Contracted demand at the Columbus site rose from 8.5 megawatts to 11 megawatts; the initial term runs to September 16, 2030, with a five-year renewal if both parties agree
Columbus Light and Water is returning a $300,000 deposit, which PowerCompute is replacing with a utility bond
Management says the site was not assessed a TVA capacity commitment charge of approximately $1.5 million per megawatt above the first five megawatts
On September 30, 2026, subsidiary Boost Run LLC entered a Service Agreement with Cohere Inc to provide dedicated GPU cloud computing infrastructure. Cohere has committed to pay approximately $525.6 million over the term, part of it as a prepayment, subject to delivery and acceptance. Payments depend on infrastructure delivery, and Cohere can terminate and receive refunds of prepaid amounts in certain cases, including if a minimum amount is not accepted by July 15, 2027.
Cohere has committed to pay approximately $525.6 million over the Agreement term, subject to delivery and acceptance requirements.
Each rack has a term of approximately five years from Cohere's acceptance; acceptance of the initial infrastructure is expected to begin in the second quarter of 2027.
If a specified minimum amount of infrastructure is not accepted by July 15, 2027, Cohere may terminate and receive a refund of all prepaid amounts.
Boost Run Inc. has guaranteed refunds of prepaid amounts, up to the prepayment received and not applied against fees.
Aviat Networks disclosed that its subsidiary, Aviat Networks (India) Ltd., signed an intellectual property license agreement with Dixon Electro Appliances Private Ltd. on September 30, 2026. Under the deal, Dixon will manufacture and sell approved WTM 4000 microwave radios to select Indian telecommunications operators, while Aviat keeps its intellectual property and continues to provide software and services. The filing gives no financial terms, so its effect on shareholders' results cannot be measured from the document.
Agreement dated September 30, 2026, between Aviat Networks (India) Ltd. and Dixon Electro Appliances Private Ltd. (DEAPL)
Dixon may manufacture and sell approved WTM 4000 family products to select Indian telecommunications operators
Aviat retains its intellectual property and continues to provide software and services
Aviat estimates Indian microwave market demand at approximately 250,000 links over the next four years; the filing states no revenue or profit figures for the agreement
Equillium said it received ethics committee approval and clearance from Australia's Therapeutic Goods Administration under the Clinical Trial Notification scheme for a Phase 1 trial of EQ504. The company expects to begin dosing healthy participants by early November 2026, moving the drug candidate closer to clinical data.
Approvals: Human Research Ethics Committee approval and TGA clearance in Australia for the EQ504 Phase 1 trial
Timing: Company expects to begin dosing healthy participants by early November 2026
Design: Randomized, double-blinded, placebo-controlled, single-center study with three parts, including a 10-day multiple ascending dose portion and a food effect cohort
The Sponsor of the Grayscale Avalanche Staking ETF (GAVA) signed an agreement on September 29, 2026 with Anchorage Digital Bank N.A. so that Anchorage can hold a portion of the Trust's AVAX alongside Coinbase, which remains the primary custodian. The filing does not state how much AVAX will move to Anchorage, and it notes that shareholders cannot be assured the custodian's insurance will cover losses.
Agreement dated September 29, 2026 under the Sixth Amendment to the Master Custody Service Agreement with Anchorage Digital Bank N.A.
Coinbase Custody Trust Company remains the Trust's primary custodian; the Sponsor has not determined the amount of AVAX to move to Anchorage.
Anchorage is required to carry commercial crime insurance or a fidelity bond of at least $100 million in the aggregate, though the Sponsor cannot assure coverage will be adequate.
The Sponsor, on behalf of the Grayscale Sui Staking ETF, entered into a Sixth Amendment on September 29, 2026 to the Master Custody Service Agreement with Anchorage Digital Bank N.A., making the Trust a party to the agreement. Coinbase Custody Trust Company remains the Trust's primary custodian, and the Sponsor has not yet decided how much SUI will move to Anchorage Digital.
Sixth Amendment dated September 29, 2026 to the Master Custody Service Agreement originally dated August 8, 2025
Coinbase Custody Trust Company, LLC remains the primary custodian; the Sponsor has not determined the amount of SUI to move to Anchorage Digital
Anchorage Digital must maintain insurance including commercial crime coverage or a fidelity bond with limits of not less than $100 million in the aggregate; the filing says shareholders cannot be assured coverage will be adequate
The Sponsor, on behalf of the Grayscale Chainlink Trust ETF, entered into a custody agreement with Anchorage Digital Bank N.A. on September 29, 2026, under which Anchorage Digital will hold a portion of the Trust's LINK alongside its existing primary custodian, Coinbase. The Sponsor has not yet determined how much LINK will move to Anchorage Digital, and the filing states that Coinbase remains the primary custodian.
Agreement dated September 29, 2026 is a Sixth Amendment to a Master Custody Service Agreement dated August 8, 2025
Coinbase Custody Trust Company remains the Trust's primary custodian; the total amount moving to Anchorage Digital has not been determined
Anchorage Digital must maintain insurance, including commercial crime coverage or a fidelity bond, with limits of not less than $100 million in the aggregate
On September 29, 2026, the Fund's manager signed a Sixth Amendment with Anchorage Digital Bank N.A., making the Fund a party to a custody agreement under which Anchorage Digital will hold a portion of the Fund's Fund Components. Coinbase Custody Trust Company remains the primary custodian, and the manager has not yet decided how much will move to Anchorage Digital, so shareholders' exposure to custody arrangements changes but the filing does not state an effect on the Fund's value.
Agreement dated September 29, 2026; Anchorage Digital custody agreement dated as of August 8, 2025, as amended
Coinbase Custody Trust Company, LLC remains the Fund's primary custodian
Anchorage Digital is required to maintain commercial crime insurance or a fidelity bond with limits of not less than $100 million in the aggregate
The manager has not determined the total amount of Fund Components to be moved to Anchorage Digital
The Sponsor amended participant agreements with Macquarie Capital (USA) and Virtu Americas to allow in-kind creations and redemptions of Shares, and the Trust added Anchorage Digital Bank as an additional custodian for a portion of its DOGE holdings. The filing says Baskets will not yet be created or redeemed in-kind because regulatory approval has not been obtained, and that Coinbase remains the primary custodian.
Participant agreements with Macquarie Capital (USA) Inc. and Virtu Americas LLC were amended to permit in-kind creations and redemptions.
The Anchorage Digital custody amendment was signed September 29, 2026; the Sponsor has not determined how much DOGE will move to Anchorage Digital.
Anchorage Digital must maintain commercial crime insurance or a fidelity bond with limits of not less than $100 million in the aggregate, though the Sponsor cannot assure that coverage will be adequate.
A Basket is 10,000 Shares, and in-kind orders await In-Kind Regulatory Approval from NYSE Arca.
On September 29, 2026, the Sponsor on behalf of Grayscale XRP Trust ETF entered into an amendment to a custody agreement with Anchorage Digital Bank N.A., which will hold a portion of the Trust's XRP while Coinbase Custody remains the primary custodian. The filing also discloses amended participant agreements with Macquarie Capital (USA) Inc. and Virtu Americas LLC that allow in-kind creations and redemptions, though the exhibit states in-kind orders are not yet available pending regulatory approval.
September 29, 2026: Sponsor entered the Sixth Amendment to the Master Custody Service Agreement dated August 8, 2025, with Anchorage Digital Bank N.A.
Anchorage Digital will custody a portion of the Trust's XRP; Coinbase Custody Trust Company remains primary custodian; the amount to be moved has not been determined.
Participant agreements amended with Macquarie Capital (USA) Inc. and Virtu Americas LLC to permit in-kind creations and redemptions; exhibit says in-kind orders await In-Kind Regulatory Approval.
Anchorage must maintain crime insurance or a fidelity bond of at least $100 million in the aggregate; the filing says shareholders cannot be assured coverage will be adequate.
The Zcash ETF's sponsor, Grayscale Investments Sponsors, LLC, signed an agreement on September 29, 2026 under which Anchorage Digital Bank N.A. will hold part of the trust's ZEC alongside Coinbase Custody, which remains primary custodian. The filing says the sponsor has not yet decided how much ZEC will move to Anchorage, so the effect on shareholders depends on that undisclosed amount.
Agreement dated September 29, 2026 is the Sixth Amendment to a Master Custody Service Agreement dated August 8, 2025
Coinbase Custody Trust Company, LLC remains the primary custodian; the sponsor has not determined how much ZEC will move to Anchorage Digital
Anchorage Digital must carry insurance including commercial crime coverage or a fidelity bond of at least $100 million in aggregate; the filing says shareholders cannot be assured coverage will cover losses
Trust fees paid to Anchorage Digital are a Sponsor-paid Expense
The Trust's sponsor entered into an agreement on September 30, 2026 that adds BitGo Bank & Trust as a custodian for a portion of the Trust's HYPE holdings, alongside existing custodian Anchorage Digital Bank. The sponsor says the move reflects its ongoing risk management approach as the Trust grows, but has not yet decided how much HYPE will be moved to BitGo.
Agreement dated September 30, 2026 adds BitGo Bank & Trust, National Association, as an additional custodian for the Trust's HYPE.
Anchorage Digital Bank N.A. remains the Trust's primary custodian; the sponsor has not determined the amount to move to BitGo.
BitGo holds the Trust's HYPE in a segregated account with keys held by BitGo; fees paid to BitGo are a Sponsor-paid expense.
Korro Bio said it has dosed the first cohort of participants in the ANCHOR Phase 1/2 clinical trial of KRRO-121, a treatment in development for hyperammonemia in urea cycle disorders and hepatic encephalopathy. The filing describes a clinical milestone in an early-stage program and contains no financial results, guidance, or changes to the company's financing or management.
First cohort of healthy volunteers dosed with a single 2mg/kg dose in Australia
Dosing of urea cycle disorder patients expected to start in the first half of 2027
Interim readout expected in the second half of 2027
VIDA Global Inc. announced on October 5, 2026 a new pricing option that charges business customers for verified results from its digital employees rather than usage, offered alongside its existing usage-based billing. The filing contains no financial figures, so it does not show any effect on revenue or earnings.
Coya Therapeutics announced that it has fully enrolled the planned 120 patients in its ongoing Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS). Topline data from the double-blind treatment phase are expected in early Q2 2027, a key clinical milestone for the company's lead program.
Full enrollment of the planned 120 patients in the ALSTARS Trial (NCT07161999) announced October 5, 2026
Additional participants already in active screening may enroll if deemed eligible
Topline data from the 24-week double-blind treatment phase anticipated in early Q2 2027
Primary endpoint is change in ALSFRS-R total score from baseline to Week 24 compared with placebo
TELA Bio said the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. The company said Liora is the first implant fully developed in its ISO 8 certified cleanroom in Malvern, PA, and that it expands TELA Bio's footprint in the soft tissue reconstruction market. The filing does not include financial figures or sales expectations for the product.
FDA granted 510(k) clearance for the Liora Monofilament Scaffold, announced October 5, 2026
Liora is described as a fully resorbable surgical mesh device for soft tissue reinforcement
Liora is the first implant fully developed in the company's ISO 8 certified cleanroom in Malvern, PA
More details are expected on the third quarter earnings call, expected in early November
BioAge Labs said the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102 in adults with diabetic macular edema. The filing also updated the trial design, with topline results expected in the second half of 2027, which is a clinical milestone rather than a financial result for shareholders.
First participant dosed in QUELL-DME, a Phase 2 trial of oral BGE-102, an NLRP3 inhibitor
Trial plans about 180 participants randomized 1:1:1 across three arms over 12 weeks of dosing, with a four-week follow-up
Primary endpoint is change in best-corrected visual acuity at week 12
Topline results expected in the second half of 2027
Century Therapeutics presented nonclinical data on its iPSC-derived islet replacement therapy CNTY-813 at the European Association for the Study of Diabetes meeting in Milan on October 2, 2026. The company reiterated that its CNTY-813 IND submission remains on track for the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.
Data showed CNTY-813 maintained glycemic control in diabetic mice for over eleven months until graft removal.
Five clinical-scale manufacturing batches produced consistent final product, using a 29-day process.
IND submission is expected in Q4 2026; initial clinical data are anticipated in 2H 2027.
The filing reports no financial results; the update covers preclinical data and development timing only.
Cullinan Therapeutics announced on October 1, 2026 that it has initiated a New Drug Application submission to the FDA for zipalertinib plus platinum-based chemotherapy in previously untreated EGFR exon 20 insertion NSCLC, under the FDA's Real-Time Oncology Review program. The company expects to complete the submission by year-end 2026, and the filing does not disclose financial results or a change in guidance. For shareholders, this is a regulatory milestone that also keeps milestone payments from partner Taiho in view.
NDA submission initiated on October 1, 2026 under the FDA's Real-Time Oncology Review program; completion expected by year-end 2026
Submission is based on Phase 3 REZILIENT3 trial data, which met its primary endpoint for median progression-free survival
A separate NDA for zipalertinib monotherapy remains under FDA review with a PDUFA target action date of February 27, 2027
Company is eligible for a $30.0 million payment from Taiho on U.S. approval in second-line treatment and up to $100.0 million on first-line approval
Nexalin Technology entered a 10-year exclusive distribution agreement, effective September 22, 2026, with Inovanexa Medical Technologies S.A. for its Nexalin Sync device in seven countries. The filing discloses no purchase value or revenue figures, and the company says it is pre-revenue, so the financial effect for shareholders depends on purchase orders and the performance requirements that the distributor must meet.
Exclusivity covers Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, with a 10-year initial term that renews automatically if performance requirements are met.
The 8-K says the distributor must place an initial binding order for five devices at signing, with a clinical pilot targeted within 90 days. The press release says the binding order is for 10 devices, with five delivered immediately.
After the first 30 devices are purchased, the distributor must set up a local manufacturing facility in Brazil at its own cost, and Nexalin would receive per-device compensation and disposable royalties.
The filing states the distributor is not otherwise obligated to buy more devices, and the company's risk disclosures say it may never recognize revenue beyond the initial order.
Linkhome Holdings announced the launch of GPU Marketplace 2.0, a public marketplace where customers can rent computing capacity from individuals and data centers with available GPU resources. The company said it has not generated material revenue from the marketplace to date and is not providing revenue or earnings guidance for it, so the launch does not yet change the company's financial outlook.
Launched October 1, 2026 through the Linkhome AI platform run by subsidiary Linkhome Technologies Inc.
Compute providers must apply to register and meet the platform's technical, security and compliance requirements.
The company has not generated material revenue from GPU Marketplace 2.0 and gives no revenue or earnings guidance for it.
The filing states there is no assurance providers will register or that the marketplace will meet customer demand.
Gain Therapeutics said a poster on long-term open-label extension data for rexaceract in Parkinson's disease will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, October 4-8, 2026. The company reported that MDS-UPDRS motor scores were stable over 12 months in 12 evaluable participants and that preliminary data show the drug is generally well tolerated, and it expects to submit a new Phase 2 protocol to the FDA in the coming weeks.
Poster to be presented at the Congress in Seoul, Korea, October 4-8, 2026
12 of 13 evaluable patients completed 12 months of dosing as of August 31, 2026; one more is scheduled to finish in November 2026
MDS-UPDRS motor scores stable over 12 months in the 12 evaluable participants, with no clinically meaningful progression
Company expects to start the Phase 2 trial in Parkinson's disease in the first quarter of 2027
Allarity Therapeutics announced an update on its Drug Response Predictor (DRP) technology, recently awarded patents and CLIA-certified in-house lab, which it says support stenoparib's clinical development and external partnership opportunities. The filing contains no financial results, guidance or financing figures, so the update is a development-stage business announcement rather than a measure of current performance.
Recently awarded patents and CLIA certification of the in-house lab allow Allarity to extend the test as a companion diagnostic and retain sole control of the clinical test
The stenoparib-DRP is a 414-gene expression signature; an exploratory analysis presented at AACR 2026 linked higher DRP scores to longer overall survival in a prior Phase 2 ovarian cancer cohort
Allarity states stenoparib remains its principal development focus, with external partnerships an additional opportunity
D-Wave Quantum Inc. launched a beta program on October 1, 2026, giving select customers early access to its gate-model quantum computing simulator ahead of general availability. The filing names BBVA, FirstQFM, Florida Atlantic University and the Jülich Supercomputing Centre as participants. The filing contains no financial results, guidance or financial figures, so the announcement is a product development milestone rather than a change in reported financial performance.
Beta program launched October 1, 2026, with select customers getting early access to the simulator before general availability
Named participants include BBVA, FirstQFM, Florida Atlantic University and the Jülich Supercomputing Centre
Simulator is accessed through the Leap quantum cloud service and Ocean SDK, and is built on D-Wave's dual-rail superconducting gate-model technology
A related peer-reviewed study published in Nature validated a foundational element of the dual-rail architecture
Brookfield announced a non-binding framework agreement between the U.S. Government and South Korea to support up to $120 billion of Korean investment in eight large nuclear reactors in the U.S. Brookfield is a shareholder in Westinghouse alongside Cameco, and the framework includes a planned Korean equity investment of 5% to 10% in Westinghouse, but the filing does not quantify Brookfield's own financial effect.
Up to $120 billion of Korean investment to help finance eight large U.S. reactors
Six Westinghouse AP1000 reactors across three two-unit plants, plus two APR1400 reactors, on U.S. federal sites
Korea would make a cornerstone equity investment of between 5% and 10% in Westinghouse
Terms are non-binding and subject to final negotiations
On September 24, 2026, a Zone Frontier subsidiary entered a Ground Lease covering about 4,077 acres in Potter County, Texas, for the West Texas data center campus it is developing with HST Technologies. Base rent starts only when construction begins on each site area, and the company can terminate the lease before its inspection period ends, with a refund of its $250,000 deposit subject to a partial non-refundable portion. The lease's commencement depends on conditions such as utility commitments for at least 200 MW of firm service, so the project's path to revenue remains uncertain.
Ground Lease dated September 24, 2026 covers about 4,077 acres; 200 to 800 acres may be designated for data center use and at least 1,800 acres for solar and battery storage
Initial term of 30 years with two 10-year extension options
Base rent is $6,000 per acre per year for the data center area and $1,000 per acre per year for the solar area, beginning only when construction starts on each area
Purchase option for the data center site at $100,000 per acre before on-site power commercial operation, or $135,000 per acre on or after that date; $250,000 deposit is credited against the price if exercised
Five Point Holdings extended its Development Management Agreement with Heritage Fields El Toro, LLC, owner of the Great Park Neighborhoods community, through December 31, 2028, after the prior term was set to end December 31, 2026. The base fee is unchanged at $13.5 million a year, while incentive compensation drops to 6.75% of future distributions if the agreement is not extended beyond 2028.
Amendment dated September 25, 2026 extends the DMA term to December 31, 2028 (Third Renewal Term)
Annual base fee remains $13.5 million, paid monthly, unchanged from current level
Incentive Compensation is 9% of Great Park Venture distributions; falls to 6.75% for distributions after a non-extension beyond December 31, 2028
Massimo Group entered a consulting agreement with Acorn Management Partners running from September 28, 2026 to September 27, 2027, covering investor awareness, broker outreach and related services. The company will pay $15,000 per month and may issue deferred equity worth $125,000, capped at 90,000 shares, if the engagement continues past six months, which would add to shareholder dilution.
Cash compensation of $15,000 per month under the agreement dated September 28, 2026.
Deferred equity of $125,000 (capped at 90,000 shares of common stock) is due only if the engagement continues beyond the initial six-month period.
Either party may terminate for convenience on written notice, subject to the compensation provisions.
Take-Two Interactive entered a new long-term XBOX Publisher License Agreement with Microsoft, dated September 28, 2026 and effective September 17, 2026, that replaces all of its existing Xbox publisher license agreements with Microsoft. The filing describes the company's right to develop, publish, and sell Xbox-compatible products for all Xbox devices, but it does not disclose financial terms such as payment amounts or revenue share percentages.
Agreement signed September 28, 2026, with an effective date of September 17, 2026
Supersedes and replaces all of Take-Two's existing Xbox publisher license agreements with Microsoft
Microsoft has approval rights over each game concept and final version, including packaging and marketing featuring Microsoft's marks
Either party may terminate for material breach or insolvency; full text to be filed with the 10-Q for the period ending September 30, 2026
Rank One Computing Corp (ROC) entered into an eight-year Contract for Commercial Products and Commercial Services with the U.S. Department of Justice's Executive Office for United States Attorneys to develop and support a Digital Evidence Review Platform. The filing says the aggregate potential payment is $64.3 million if all seven option periods are exercised, but only the one-year base period is funded, and the option periods are at the government's discretion and subject to appropriations.
Contract dated September 14, 2026; base period runs September 22, 2026 through September 21, 2027, with payment of $7,414,143.80 for that period.
Aggregate potential payment of $64,301,418.24 over the eight-year term if EOUSA exercises all seven option periods.
Option periods are exercisable at the government's discretion and subject to the availability of appropriations.
Company announced the award in a press release dated September 28, 2026, filed as Exhibit 99.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.